Document:

<PAGE>
                                                                    Exhibit 10.2

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                             JOINT VENTURE AGREEMENT

                                      AMONG

                         GRELAN PHARMACEUTICAL CO., LTD.

                                       AND

                        BIONUMERIK PHARMACEUTICALS, INC.

                                 AUGUST 30, 2000
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<S>                                                                             <C>
Recitals....................................................................     1

1.  Definitions.............................................................     2
    1.1   BNP7787 Products..................................................     2
    1.2   Karenitecin Products..............................................     2
    1.3   Mercedes Products.................................................     2
    1.4   PDE4 Products.....................................................     2
    1.5   COX-2 Products....................................................     3
    1.6   Venture Products BN...............................................     3
    1.7   Venture Products GR...............................................     3
    1.8   Venture Products..................................................     3
    1.9   BioNumerik Improvements...........................................     3
    1.10  Grelan Improvements...............................................     3
    1.11  Improvements......................................................     3
    1.12  BioNumerik Patent Rights..........................................     4
    1.13  Grelan Patent Rights..............................................     4
    1.14  Patent Rights.....................................................     4
    1.15  Patents...........................................................     4
    1.16  Know-How..........................................................     4
    1.17  Affiliate(s)......................................................     4
    1.18  Confidential Information..........................................     5
    1.19  Effective Date....................................................     5
    1.20  Government Regulatory Approvals...................................     5
    1.21  IND Submission....................................................     5
    1.22  New Drug Application Approval or NDA Approval.....................     5
    1.23  Steering Committee................................................     5
    1.24  Stock Purchase Agreement..........................................     6
    1.25  Sublicensee.......................................................     6
    1.26  Territory.........................................................     6
    1.27  Trademarks........................................................     6

2.  LICENSE GRANTS BY BIONUMERIK............................................     6
    2.1   Research and Development Grant....................................     6
    2.2   Grant to Market, Sell and Distribute..............................     6

3.  LICENSE GRANTS AND TRANSFER BY GRELAN...................................     7
    3.1   Research and Development Grant....................................     7
    3.2   Grant to Market, Sell and Distribute..............................     7
    3.3   Transfer Regarding Rights Under Existing BNP7787 Agreement........     7

4.  SUBLICENSES AND OTHER DISTRIBUTION METHODS FOR VENTURE PRODUCTS.........     8
    4.1   Distribution Methods and Branch Office............................     8
    4.2   Identification of Sublicensees....................................     8
    4.3   Right to Grant Sublicenses........................................     8
    4.4   Division of Sublicensing Fees and Other Payments..................     9
    4.5   Third Party Offers or Statements of Interest......................     9
</TABLE>

                                       i
<PAGE>
<TABLE>
<S>                                                                             <C>
5.  RIGHTS OF FIRST REFUSAL FOR VENTURE PRODUCTS BN AND DEVELOPMENT RIGHTS..     9
    5.1   Right of First Refusal............................................     9
    5.2   Development Rights................................................    10
    5.3   Development Outside Territory.....................................    10

6.  INFORMATION SHARING AND DEVELOPMENT COSTS...............................    11
    6.1   Pre-Clinical Studies..............................................    11
    6.2   Government Approvals and Clinical Trials..........................    11
    6.3   Copies and Provision of Information...............................    13
    6.4   Supplies of Product for Pre-Clinical Studies and Clinical Trials..    14
    6.5   Provision of Know-How.............................................    14

7.  MANUFACTURING RIGHTS FOR VENTURE PRODUCTS AND

    PURCHASE OF APPROVED PRODUCTS BY THE VENTURE............................    15
    7.1   Manufacturing Rights for Venture Products BN .....................    15
    7.2   Manufacturing Rights for Venture Products GR .....................    16
    7.3   Distribution and Sale of Venture Products ........................    17
    7.4   Commercial Supply Arrangements ...................................    18
    7.5   Product Labeling .................................................    18

8.  STEERING COMMITTEE .....................................................    18
    8.1   Formation and Composition.........................................    18
    8.2   Duties............................................................    19
    8.3   Meetings..........................................................    19
    8.4   Recommendation Regarding Management...............................    19
    8.5   Identification of Consultants.....................................    19

9.  DEVELOPMENT AND COMMERCIALIZATION PLAN..................................    19
    9.1   General Diligence Efforts.........................................    19
    9.2   Target Development and Commercialization Plan.....................    19

10. PATENT MATTERS..........................................................    20
    10.1  BioNumerik Patent Maintenance ....................................    20
    10.2  Grelan Patent Maintenance and Assistance .........................    20
    10.3  No Present Notification of Infringement- BioNumerik ..............    21
    10.4  No Present Notification of Infringement- Grelan ..................    21
    10.5  Enforcement of Patents and Proprietary Rights ....................    21

11. IMPROVEMENTS............................................................    22
    11.1  BioNumerik Improvements Included..................................    22
    11.2  Grelan Improvements Included......................................    23
    11.3  Joint Improvements................................................    23
    11.4  Sublicense of Improvements........................................    23

12. TRADEMARKS AND TRADEMARK RIGHT..........................................    24
    12.1  ..................................................................    24
    12.2  ..................................................................    24
    12.3  ..................................................................    24
</TABLE>

                                       ii
<PAGE>
<TABLE>
<S>                                                                             <C>
13. CONFIDENTIALITY.........................................................    24
    13.1  Confidential and Proprietary Information..........................    24
    13.2  Matters Not Included as Confidential Information..................    25
    13.3  Survival of Confidentiality.......................................    26

14. PROVISION FOR VENTURE FUNDING...........................................    26

15. ACCOUNTING..............................................................    26

16. USE OF NAMES............................................................    27

17. INDEMNIFICATION.........................................................    28
    17.1  BioNumerik Indemnification........................................    28
    17.2  Grelan Indemnification............................................    28
    17.3  KI Pharma Indemnification ........................................    28

18. DURATION AND TERMINATION OF AGREEMENT...................................    29
    18.1  Duration..........................................................    29
    18.2  Termination.......................................................    29
    18.3  Effect of Expiration or Termination...............................    30

19. BIONUMERIK REPRESENTATIONS & WARRANTIES.................................    32
    19.1  Due Organization and Authority....................................    32
    19.2  Safety of Product(s)..............................................    32
    19.3  No Pending Action Against BioNumerik..............................    32

20. Grelan Representations and Warranties...................................    33
    20.1  Due Organization and Authority....................................    33
    20.2  Safety of Product(s)..............................................    33
    20.3  No Pending Action Against Grelan..................................    33

21. ASSIGNMENTS.............................................................    33
    21.1  Assignment Restrictions...........................................    33
    21.2  Sale of Business..................................................    34
    21.3  Assignment to Affiliates..........................................    33

22. MISCELLANEOUS...........................................................    34
    22.1  Regulatory Communications.........................................    34
    22.2  Adverse Events....................................................    35
    22.3  Liability Insurance...............................................    35
    22.4  Litigation........................................................    35
    22.5  Auditors..........................................................    35
    22.6  Marketing Analysis and Reports....................................    35
    22.7  Notice / Reports..................................................    36
    22.8  Severability......................................................    36
    22.9  Counterparts......................................................    36
    22.10 Warranty Disclaimer...............................................    37
    22.11 Force Majeure.....................................................    37
    22.12 Arbitration.......................................................    37
</TABLE>

                                      iii
<PAGE>
<TABLE>
<S>                                                                             <C>
    22.13 Export Controls...................................................    38
    22.14 Construction / Jurisdiction / Official Language...................    38

23. ENTIRE AGREEMENT........................................................    38

24. CAPTIONS................................................................    39

SIGNATURES..................................................................    39

ATTACHMENT A-1..............................................................    41
ATTACHMENT A-2..............................................................    42
ATTACHMENT A-3..............................................................    43
ATTACHMENT A-4..............................................................    44
ATTACHMENT A-5..............................................................    45
ATTACHMENT B-1..............................................................    46
ATTACHMENT B-2..............................................................    47
ATTACHMENT C ...............................................................    48
ATTACHMENT D................................................................    50
ATTACHMENT E................................................................    52
ATTACHMENT F................................................................    54
ATTACHMENT G................................................................    72
</TABLE>

                                       iv
<PAGE>
                                    AGREEMENT

      THIS JOINT VENTURE AGREEMENT ("Agreement") is made and entered into
effective as of August 30, 2000, by and between BIONUMERIK PHARMACEUTICALS,
INC., a Texas corporation, with its office located at 8122 Datapoint Drive,
Suite 1250, San Antonio, Texas 78229, U.S.A. (hereinafter referred to as
"BIONUMERIK") and GRELAN PHARMACEUTICAL CO., LTD., a Japanese corporation having
its place of business at Ogura Bldg. 5F, Nihonbashi Kobunacho 6-6, Chuo-ku,
Tokyo 103-0024, Japan (hereinafter referred to as "GRELAN").

                                R E C I T A L S:

      WHEREAS, GRELAN and BIONUMERIK intend to create a Delaware limited
liability company to be called KI Pharmaceuticals, L.L.C. (hereinafter referred
to as "KI PHARMA" or the "Venture") for the purpose of developing, marketing,
distributing, manufacturing and selling certain specified products in the
territory of Japan.

      WHEREAS, as described in the organization documents of KI PHARMA, KI
PHARMA will be owned 50% by BIONUMERIK, 49% by GRELAN, and 1% by Dr. Hashime
Kanazawa.

      WHEREAS, additional information describing the ownership, management,
officers, allocation of profits, and other allocations and distributions
regarding KI PHARMA will be contained in an Operating Agreement of KI PHARMA
(the "Operating Agreement"), the terms of which will be agreed to by BIONUMERIK
and GRELAN.

      WHEREAS, GRELAN and BIONUMERIK are parties to a collaboration agreement
dated as of May 28, 1996 and amended as of June 8, 1999 regarding the BNP7787
Products (as defined below) and related technology (the "Existing Agreement")
and the parties wish that GRELAN transfer certain rights it has thereunder to KI
PHARMA, without prejudice to any and all rights GRELAN or BIONUMERIK may retain,
and thereafter the Existing Agreement is immediately terminated, as described in
detail in Section 3.3 below.
<PAGE>

      WHEREAS, following creation of KI PHARMA and signing of the Operating
Agreement, KI PHARMA will agree to be bound by the terms of this Agreement.

      WHEREAS, the parties wish to enter into this Agreement to evidence the
license and transfer of certain rights to KI PHARMA and to specify certain
commitments, rights and obligations of the parties in connection with the
Venture.

      WHEREAS, the licenses and other rights granted by GRELAN and BIONUMERIK
herein are granted subject to the obligations to make payments and take other
actions provided by the parties herein.

      NOW, THEREFORE, in consideration of the terms, conditions and agreements
contained herein, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereto hereby agree as
follows:

      1. DEFINITIONS. When used in this Agreement, each of the following defined
terms shall have the meanings set forth in this Section. There are other terms
defined in this Agreement parenthetically, and such terms shall have the
meanings apparent from the context in which such terms are parenthetically
defined.

            1.1 "BNP7787 Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-1 hereto.

            1.2 "Karenitecin Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-2 hereto.

            1.3 "Mercedes Products" means the pharmaceutical formulations and
related technology described in Attachment A-3 hereto.

            1.4 "PDE4 Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-4 hereto.

                                       2
<PAGE>

            1.5   "COX-2 Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-5 hereto.

            1.6   "Venture Products BN" means the BNP7787 Products, the
Karenitecin Products, the Mercedes Products, and such other new technologies
and/or products that, in the sole discretion of BIONUMERIK, may be licensed to
KI PHARMA in the Territory.

            1.7   "Venture Products GR" means the PDE4 Products, the COX-2
Products, and such other new technologies and/or products that, in the sole
discretion of GRELAN, may be licensed to KI PHARMA in the Territory.

            1.8 "Venture Products" means the Venture Products BN and the Venture
Products GR.

            1.9 "BioNumerik Improvements" means any and all inventions,
developments, discoveries and improvements directly relating to Venture
Products, including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, and information concerning synthesis,
processes, formulations, applications, toxicity, operations, regulatory affairs
and marketing, that are developed by or for BIONUMERIK subsequent to the date of
this Agreement and during the term of this Agreement, subject in all cases to
any restrictions that may exist on the ability of BIONUMERIK to license such
inventions, developments, discoveries or improvements to KI PHARMA and/or
GRELAN, as applicable, in or outside the Territory.

            1.10 "Grelan Improvements" means any and all inventions,
developments, discoveries, and improvements directly relating to Venture
Products, including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, and information concerning synthesis,
processes, formulations, applications, toxicity, operations, regulatory affairs
and marketing, that are developed by or for GRELAN subsequent to the date of
this Agreement and during the term of this Agreement, subject in all cases to
any restrictions that may exist on the ability of GRELAN to license such
inventions, developments, discoveries or improvements to KI PHARMA and/or
BIONUMERIK, as applicable, in or outside the Territory.

            1.11   "Improvements" means the BioNumerik Improvements and the
Grelan Improvements.

                                       3
<PAGE>
            1.12 "BioNumerik Patent Rights" means those exclusive rights granted
in Japan to BIONUMERIK, that follow from any of the patent applications referred
to in Attachment B-1 hereto or from any reissue, reexamination, continuation,
divisional, continuation-in-part, utility model, or any other patent application
in Japan of BIONUMERIK whose claimed subject matter covers any of the Venture
Products BN, processes to make any of the Venture Products BN, or their use.
BIONUMERIK's current patent applications in Japan relating to the Venture
Products BN and their uses are identified in Attachment B-1 hereto.

            1.13 "Grelan Patent Rights" means those exclusive rights granted in
Japan to GRELAN, that follow from any of the patent applications referred to in
Attachment B-2 hereto or from any reissue, reexamination, continuation,
divisional, continuation-in-part, utility model, or any other patent application
in Japan of GRELAN whose claimed subject matter covers any of the Venture
Products GR, processes to make any of the Venture Products GR, or their use.
GRELAN's current patent applications in Japan relating to the Venture Products
GR and their uses are identified in Attachment B-2 hereto.

            1.14 "Patent Rights" means the BioNumerik Patent Rights and the
Grelan Patent Rights.

            1.15 "Patents" means those patents embodying the Patent Rights in
the Territory.

            1.16 "Know-How" means all data and information owned by BIONUMERIK
and/or GRELAN, as the case may be, and directly relating to the Venture
Products, including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, information concerning synthesis,
processes, formulations, applications, administration to patients, clinical
protocols, toxicity, operations, regulatory affairs and marketing, that have
been developed by or for BIONUMERIK and/or GRELAN, as the case may be, on or
before the date of this Agreement and which is useful in the development,
manufacture or sale of the Venture Product(s) in the Territory, subject in all
cases to any restrictions that may exist on the ability of BIONUMERIK and
GRELAN, as applicable, to license such Know-How to KI PHARMA, BIONUMERIK and/or
GRELAN, as applicable, in or outside the Territory.

            1.17 "Affiliates " means, with respect to each party, any
organization, company, firm, or other entity which controls, is controlled by,
or is under common control with said party. A company shall be deemed to have
control of another if it owns directly or indirectly a majority of the voting
shares of or is entitled directly or indirectly to appoint a majority of the
directors of the other company.

                                       4
<PAGE>
            1.18 "Confidential Information" means all information which is of a
confidential and proprietary nature, including without limitation, trade
secrets, inventions and unpatented Know-How and Improvements and related
technology, and any and all material information which any of the parties hereto
may acquire concerning the financial, business and marketing goals and plans of
the other parties, including the terms of this Agreement.

            1.19 "Effective Date" means the first date after which all of the
following have occurred: (a) KI PHARMA has been formed, (b) the Operating
Agreement has been signed by GRELAN, BIONUMERIK and Dr. Hashime Kanazawa, (c)
the Stock Purchase Agreement (hereinafter defined) has been signed by GRELAN and
BIONUMERIK and GRELAN has purchased BIONUMERIK preferred stock in accordance
with the terms of the Stock Purchase Agreement, and (d) KI PHARMA has agreed to
be bound as an additional party to this Agreement.

            1.20 "Government Regulatory Approvals" means all government
approvals, health registrations and/or permits, including NDA Approvals,
required for import into or manufacture in the Territory and sale and
distribution in the Territory of Venture Products.

            1.21 "IND Submission" with respect to a Venture Product means
submission of an Investigational New Drug regulatory application ("Chiken
Todoke" corresponding to an IND application in the U.S.) to authorities for
approval to initiate any new phase of human trials of the product in a
jurisdiction in the Territory.

            1.22 "New Drug Application Approval" or "NDA Approval" means
approval from the Japanese Ministry of Health and Welfare or other applicable
regulatory body, as the case may be, of a New Drug Application which authorizes
or allows the import to or manufacture in the Territory of and sale in the
Territory of a Venture Product.

            1.23 "Steering Committee" means the Steering Committee of KI PHARMA,
as such committee is further described in Section 8 hereof.

                                       5
<PAGE>
            1.24 "Stock Purchase Agreement" means that certain Stock Purchase
Agreement to be entered into by GRELAN and BIONUMERIK providing for the purchase
by GRELAN of U.S. $4 million of BioNumerik Series G Preferred Stock.

            1.25 "Sublicensee" means an entity to whom KI PHARMA has granted
pursuant to Section 4.3 or 5.1 a sublicense to develop, market, sell, distribute
or otherwise commercially dispose of Venture Products within the Territory,
based on KI PHARMA's exclusive license set forth in Sections 2.2 and 3.2 and its
rights transferred by GRELAN under Section 3.3.

            1.26 "Territory" means Japan and any of its possessions or
territories.

            1.27 "Trademarks" means (i) the brand name(s) selected by KI PHARMA,
with the approval of BIONUMERIK and GRELAN, for Venture Products in the
Territory, and (ii) all Katakana or Hiragana transliterations of the names
referenced above, and all equivalents thereof, for use with Venture Products.

      2. LICENSE GRANTS BY BIONUMERIK.

             2.1 Research and Development Grant. Effective as of the Effective
Date, BIONUMERIK hereby grants to KI PHARMA and GRELAN an exclusive license
under the BioNumerik Patent Rights, Know-How and BioNumerik Improvements to
conduct and have conducted research and development of the Venture Products BN
in the Territory for the purpose of obtaining Government Regulatory Approvals in
the Territory.

            2.2 Grant to Market, Sell and Distribute. Effective as of the
Effective Date, BIONUMERIK hereby grants to KI PHARMA an exclusive license under
the BioNumerik Patent Rights, Know-How, BioNumerik Improvements and Trademarks
to import Venture Products BN into the Territory and/or market, sell, distribute
or otherwise commercially dispose of Venture Products BN in the Territory during
the term of this Agreement. Except as otherwise provided in this Agreement, (a)
BIONUMERIK shall not, without prior written consent from GRELAN, directly or
indirectly, except through KI PHARMA, import Venture Products BN into the
Territory nor distribute or sell Venture Products BN in the Territory, and (b)
KI PHARMA and GRELAN without prior written consent from BIONUMERIK shall not
directly or

                                       6
<PAGE>
indirectly manufacture Venture Products BN in the Territory or develop,
manufacture, promote, distribute or sell Venture Products BN outside the
Territory or export Venture Products BN from the Territory.

      3. LICENSE GRANTS AND TRANSFER BY GRELAN.

            3.1 Research and Development Grant. Effective as of the Effective
Date, GRELAN hereby grants to KI PHARMA an exclusive license under the Grelan
Patent Rights, Know-How and Grelan Improvements to conduct and have conducted
research and development of the Venture Products GR in the Territory for the
purpose of obtaining Government Regulatory Approvals in the Territory.

            3.2 Grant to Market, Sell and Distribute. Effective as of the
Effective Date, GRELAN hereby grants to KI PHARMA an exclusive license under the
Grelan Patent Rights, Know-How, Grelan Improvements and Trademarks to market,
sell, distribute or otherwise commercially dispose of Venture Products GR in the
Territory during the term of this Agreement. Except as otherwise provided in
this Agreement, (a) GRELAN shall not directly or indirectly, except through KI
PHARMA, distribute or sell Venture Products GR in the Territory, and (b) KI
PHARMA and BIONUMERIK shall not directly or indirectly develop or manufacture
Venture Products GR in the Territory, import Venture Products GR into the
Territory or develop, manufacture, promote, distribute or sell Venture Products
GR outside the Territory or export Venture Products GR from the Territory.

            3.3 Transfer Regarding Rights Under Existing BNP7787 Agreement.
Effective as of the Effective Date, GRELAN hereby transfers to KI PHARMA all
rights with respect to the import, marketing, sale, distribution or disposal of
the BNP7787 Products under the Existing Agreement. Following the Effective Date,
all other rights and obligations under such Existing Agreement shall terminate,
provided that (i) BIONUMERIK shall have no obligation to repay any amounts
previously paid by GRELAN under such Existing Agreement, (ii) BIONUMERIK shall
continue after the Effective Date to have the right to use all data and results
obtained from the pre-clinical and non-clinical studies and clinical trials
obtained by GRELAN under the Existing Agreement up to the execution of this
Agreement, and (iii) the confidentiality obligations of GRELAN and BIONUMERIK
contained in the Existing Agreement shall remain and continue in full force and
effect in accordance with their terms. In addition, GRELAN shall have the right
to negotiate in the future with KI PHARMA to obtain an exclusive sublicense to
market, sell, promote and distribute (a) the BNP7787 Products in the Territory,
and (b) the PDE4 Products and the COX-2 Products in the Territory and GRELAN
shall retain the exclusive right to develop (i) the BNP7787

                                       7
<PAGE>
Products in the Territory and (ii) the PDE4 Products and the COX-2 Products in
the Territory, subject in all cases to GRELAN's performance of product
development in the Territory and the approval rights contained in Section 4.3
hereof (including BIONUMERIK's right to approve the terms of any sublicense by
KI PHARMA to GRELAN of the right to market, sell, promote, distribute or
otherwise commercially dispose of the BNP7787 Products in the Territory).

      4. SUBLICENSES AND OTHER DISTRIBUTION METHODS FOR VENTURE PRODUCTS.

            4.1 Distribution Methods and Branch Office. The method in which KI
PHARMA will market, sell, distribute or otherwise commercially dispose of
Venture Products in the Territory is described in Section 7.3 hereof. If KI
PHARMA establishes or otherwise owns an Affiliate in the Territory, such
Affiliate may become a Sublicensee, subject to the prior written consent of the
parties hereto. A Japanese branch office or other office of KI PHARMA will be
established as quickly as possible after the Effective Date, in the premises of
GRELAN in Nihonbashi, Chuo-ku, Tokyo, Japan.

            4.2 Identification of Sublicensees. Dr. Hashime Kanazawa (or another
designated qualified senior management employee of GRELAN), at the request of
the Steering Committee, will have the responsibility to identify and present to
KI PHARMA potential third parties to sublicense certain Venture Products for the
Territory.

            4.3 Right to Grant Sublicenses. KI PHARMA shall have the right to
grant sublicenses to market, sell, distribute or otherwise commercially dispose
of Venture Products within the Territory subject to the following conditions:
(i) the parties hereto shall discuss in good faith with respect to the timing of
a formal request and authorization to pursue any potential sublicense by KI
PHARMA with respect to Venture Products but BIONUMERIK shall have the right to
decide such timing with respect to Venture Products BN, and GRELAN shall have
the right to decide such timing with respect to Venture Products GR; (ii) in
addition, (a) BIONUMERIK will have the final right and authority to accept or
refuse any potential Sublicensee for Venture Products BN in the Territory, and
(b) GRELAN will have the final right and authority to accept or refuse any
potential Sublicensee for Venture Products GR in the Territory; provided that if
GRELAN is the potential Sublicensee for a particular Venture Product GR, then
the

                                       8

<PAGE>
Steering Committee shall have the final right and authority to accept or refuse
such sublicense, and provided further that BIONUMERIK and GRELAN shall not
refuse such Sublicensees unreasonably.

             4.4 Division of Sublicensing Fees and Other Payments. In
consideration for the valuable nature of the Patent Rights, Know-How and
Improvements and the access to potential new partners they will give to KI
PHARMA, (i) in the event a sublicense fee or other up-front or milestone payment
amount due on or before the relevant NDA Approval (collectively, the "Up-front
Payment") is paid by any Sublicensee or other third party for distribution,
marketing and/or sales rights to a Venture Product BN in the Territory, then
BIONUMERIK will be paid [**] of such payment and GRELAN will be paid  [**] of
such payment, and (ii) in the event the Up-front Payment is paid by any
Sublicensee or other third party for distribution, marketing and/or sales rights
to a Venture Product GR in the Territory, then GRELAN will be paid [**] of such
payment and BIONUMERIK will be paid [**] of such payment. All royalty payments
due after the relevant NDA Approval (the "Royalties") and any additional amounts
received from any Sublicensee or other third party in connection with a Venture
Product being sold by or for the benefit of KI PHARMA to a Japanese wholesaler,
distributor, hospital, or pharmacy, after payment of the manufacturing price,
Royalties, and Up-front Payments, shall be paid [**] to GRELAN and [**] to
BIONUMERIK.

             4.5 Third Party Offers or Statements of Interest. If a third party
makes a statement of interest or offer to sublicense a Venture Product in the
Territory to any of the parties hereto, then the notified party shall notify the
other parties hereto with respect to the indication of interest or offer and
shall provide the other parties hereto with copies of any correspondence and a
summary of any meeting regarding such matter.

      5. RIGHTS OF FIRST REFUSAL FOR VENTURE PRODUCTS BN AND DEVELOPMENT RIGHTS.

             5.1 Right of First Refusal. Subject to the conditions contained in
Section 4.3, effective as of the Effective Date GRELAN is hereby granted by KI
PHARMA a right of first refusal to negotiate to obtain a license for itself for
any Venture Products BN that KI PHARMA proposes to license to third parties. The
first refusal right granted herein with respect to each particular product will
expire forty- five (45) days after GRELAN's receipt of a written notice from KI
PHARMA identifying such Venture Product BN proposed to be licensed to a third
party. If no proposal to obtain a license for such product is made to KI PHARMA
by GRELAN within such time period, GRELAN's right of first refusal shall

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       9
<PAGE>
terminate with respect to such product. In the event GRELAN does make a proposal
for the product within such time period, then KI PHARMA, GRELAN, and BIONUMERIK
will negotiate in good faith during the remainder of such 45 day notice period
and for an additional 90 day period (the "Negotiation Period") in an effort to
enter into a license agreement for such product on mutually agreeable terms. If
a license has not been executed by the end of the Negotiation Period, then (i)
the negotiations shall be deemed deadlocked and KI PHARMA shall, upon the
request of BIONUMERIK, use best efforts to seek another potential licensee with
respect to such product, and (ii) KI PHARMA shall be free to enter into such
third party license, provided the terms of such license are no more favorable to
such third party licensee than the terms last proposed to GRELAN.

            5.2 Development Rights. Effective as of the Effective Date, KI
PHARMA shall have the right, with the right to sublicense, to develop all
Venture Products in the Territory in accordance with the terms of this Agreement
and with the assistance of GRELAN as provided herein. Unless otherwise agreed by
the parties, BIONUMERIK will have the right to develop all Venture Products BN
outside of the Territory and GRELAN will have the right to develop all Venture
Products GR outside of the Territory. BIONUMERIK shall be solely responsible for
its licensing or development activities concerning Venture Products BN outside
the Territory.

            5.3 Development Outside Territory. Upon future mutual written
agreement by BIONUMERIK and GRELAN and if such rights are then available, KI
PHARMA may market, sell and distribute certain specified Venture Products in
other parts of Asia in addition to Japan. Notwithstanding the foregoing, GRELAN
shall remain free to license the rights to Venture Products GR outside of the
Territory in its sole discretion without the consent or approval of KI PHARMA or
BIONUMERIK; and BIONUMERIK shall remain free to license the rights to Venture
Products BN outside the Territory in its sole discretion without the consent or
approval of KI PHARMA or GRELAN. In addition to the foregoing, nothing in this
Agreement shall impact or restrict (a) the ability of GRELAN to develop, market,
sell, distribute, license, or otherwise commercially dispose of Venture Products
GR outside of the Territory in its sole discretion without the consent or
approval of KI PHARMA or BIONUMERIK, or (b) the ability of BIONUMERIK to
develop, market, sell, distribute, license, or otherwise commercially dispose of
Venture Products BN outside of the Territory in its sole discretion without the
consent or approval of KI PHARMA or GRELAN.

                                       10
<PAGE>
      6. INFORMATION SHARING AND DEVELOPMENT COSTS.

            6.1 Pre-Clinical Studies. GRELAN agrees at its sole expense to
sponsor and conduct (or have sponsored and conducted) all necessary additional
pre-clinical and non-clinical studies and tests required by the Japanese
Ministry of Health and Welfare (the "MHW") or other local regulatory agency in
the Territory in connection with commencing and conducting human clinical trials
with respect to the Venture Products in the Territory and with respect to the
manufacture (or importation into the Territory), sale and distribution of
Venture Products in the Territory. BIONUMERIK will provide free of charge to KI
PHARMA and GRELAN all pre-clinical data, clinical research protocols, and
clinical trials data and information previously or hereafter developed by
BIONUMERIK that were used and/or are necessary to support United States Food and
Drug Administration ("FDA") regulatory submissions to support regulatory
applications for the Venture Products BN in the Territory. GRELAN will provide
free of charge to KI PHARMA and BIONUMERIK all pre-clinical data, clinical
research protocols, and clinical trials data and information previously or
hereafter developed by GRELAN that are necessary to support regulatory
submissions to support regulatory applications for the Venture Products GR in
the Territory.

            6.2 Government Approvals and Clinical Trials.

                  6.2.1. GRELAN agrees to (a) conduct or cause to be conducted
all clinical trials and other studies of any nature of the Venture Products
necessary or desirable for efficiently obtaining Government Regulatory Approvals
in the Territory and (b) prepare and submit all documents necessary or desirable
for obtaining Government Regulatory Approvals in the Territory. GRELAN shall be
solely responsible for paying the costs of such clinical development and
regulatory approvals described in the previous sentence and GRELAN shall
reimburse KI PHARMA for all costs of any such clinical development and
regulatory approvals paid by KI PHARMA. If permitted by laws in the Territory,
the Government Regulatory Approvals for Venture Products shall be obtained in
the name of KI PHARMA, and GRELAN shall provide such additional assistance as
may be necessary to assure that such Approvals are obtained in the name of KI
PHARMA. Such assistance shall include, without limitation, acting as an agent of
KI PHARMA where necessary to facilitate the regulatory process. If the
Government Regulatory Approvals are not permitted to be obtained by KI PHARMA in
the name of KI PHARMA, then, with the consent of GRELAN and BIONUMERIK (which
consent will not be unreasonably withheld) such approvals will be obtained in
the name of GRELAN. To the extent permitted by laws in the Territory,

                                       11
<PAGE>
BIONUMERIK agrees to assist and support the process of obtaining the Government
Regulatory Approvals by providing input and assistance from Dr. Frederick H.
Hausheer regarding the design and conduct of preclinical experiments, clinical
protocols and trials, preparation of regulatory submissions and review, analysis
and presentation of laboratory and other non-clinical data. BIONUMERIK shall
have the right to review all draft and final clinical protocols prior to
initiation of any clinical trial in the Territory for Venture Products BN.

                  6.2.2. GRELAN shall provide BIONUMERIK and KI PHARMA with
copies of all data and developments which arise from research and development
carried out on the Venture Products pursuant to Sections 6.1 and 6.2.1. KI
PHARMA shall have ownership (including reservation of the right to use in the
Territory in accordance with this Agreement) of all data and results obtained by
GRELAN or KI PHARMA from the pre-clinical and non-clinical studies and clinical
trials pursuant to Sections 6.1 and 6.2.1 (the "Data and Results"). Unless
otherwise agreed by the parties hereto, without any further payment, BIONUMERIK
is granted the non-exclusive right, with the right to sublicense, to use the
Data and Results related to Venture Products BN outside the Territory for the
purpose of supporting pre-clinical studies, clinical trials and product
regulatory approval and development in areas outside the Territory. Unless
otherwise agreed by the parties hereto, without any further payment, GRELAN is
granted the non-exclusive right, with the right to sublicense, to use the Data
and Results related to Venture Products GR outside the Territory for the purpose
of supporting pre-clinical studies, clinical trials and product regulatory
approval and development in areas outside the Territory. In addition, without
any further payment, KI PHARMA and GRELAN may use the Data and Results to
support the development, sale and distribution of Venture Products in the
Territory (and in other parts of Asia subject to Section 5.3) in accordance with
this Agreement during the term of this Agreement.

                   6.2.3. BIONUMERIK shall comply with applicable Japanese
Pharmaceutical Law and any other applicable governmental requirements in the
Territory regarding manufacture in and import into the Territory and development
and marketing in the Territory of the Venture Products, with relation to actions
by BIONUMERIK.

                                       12
<PAGE>
            6.3 Copies and Provision of Information.

                  6.3.1. KI PHARMA and GRELAN will keep BIONUMERIK regularly and
fully informed of the preclinical and clinical process regarding the Venture
Products. KI PHARMA and GRELAN also shall keep BIONUMERIK regularly and fully
informed of the status of the Government Regulatory Approvals process on a
current basis and furnish BIONUMERIK, upon BIONUMERIK's reasonable request, with
English version copies of all important documents, data and other information
supplied to or received from the Japanese Government or other approval authority
in connection with the applications for the Government Regulatory Approvals.
Upon receipt of each Government Regulatory Approval, KI PHARMA and GRELAN shall
promptly furnish BIONUMERIK English version copies or other satisfactory
evidence thereof.

                  6.3.2. BIONUMERIK shall provide KI PHARMA and GRELAN with
copies of all information generated or controlled by it in the course of
satisfying regulatory requirements in the United States and/or Europe related to
any Venture Products BN that may be useful or necessary in obtaining Government
Regulatory Approvals in the Territory, such as IND applications, annual reports,
protocol amendments, IND amendments, and related documents ("IND and Related
Information"). If BIONUMERIK grants a license for commercial distribution of any
Venture Products BN in areas outside the Territory, BIONUMERIK agrees to use its
best efforts to provide in any agreement hereinafter signed with respect to such
license that the licensee under such license shall provide KI PHARMA and GRELAN
with all data and information generated by such licensee with respect to such
products for supporting the development of such products in the Territory.
GRELAN shall provide KI PHARMA and BIONUMERIK with copies of all information
generated or controlled by it in the course of satisfying regulatory
requirements in the United States and/or Europe related to Venture Products GR
that may be useful or necessary in obtaining Governmental Regulatory Approvals
in the Territory, such as IND and Related Information. If GRELAN grants a
license for commercial distribution of any Venture Products GR in areas outside
the Territory, GRELAN agrees to use its best efforts to provide in any agreement
hereinafter signed with respect to such license that the licensee under such
license shall provide KI PHARMA and BIONUMERIK with all data and information
generated by such licensee with respect to such products for supporting the
development of such products in the Territory. In the event a prospective
licensee for the commercial distribution of Venture Products in areas outside
the Territory will not agree to the sharing of all data and information as
provided above, each of BIONUMERIK and GRELAN will consult with KI PHARMA prior
to signing any license agreement with such party and each of BIONUMERIK and

                                       13
<PAGE>
GRELAN will use its best efforts to facilitate and provide an opportunity for
discussion among GRELAN, BIONUMERIK and such prospective licensee with respect
to a mutually satisfactory arrangement for the sharing of data and information.
For purposes of this provision, "best efforts" shall mean those reasonable
commercial efforts that would be used by reasonable business persons in a
similar situation.

                  6.3.3 GRELAN and KI PHARMA will provide BIONUMERIK with
marketing, pricing, patent, product and distribution information regarding the
Venture Products and any potentially competitive products in the Territory,
except to the extent restricted by law, other licenses or similar agreements to
which GRELAN is a party. BIONUMERIK and KI PHARMA will provide GRELAN with
marketing, pricing, patent, product and distribution information regarding the
Venture Products and any potentially competitive products outside the Territory,
except to the extent restricted by law, other licenses or similar agreements to
which BIONUMERIK is a party.

            6.4 Supplies of Product for Pre-Clinical Studies and Clinical
Trials. If requested by KI PHARMA and/or GRELAN, all supplies of Venture
Products BN required by GRELAN and/or KI PHARMA in order to conduct the studies
described in Sections 6.1 and 6.2 shall be furnished by BIONUMERIK to GRELAN
and/or KI PHARMA at a price equal to BIONUMERIK's actual cost to purchase or
manufacture the materials (including a reasonable overhead amount), plus
freight, transport, insurance, and customs, and duty charges incurred in
delivering the materials to GRELAN (and/or KI PHARMA's office in Japan), but
shall exclude any profit element. In accordance with Sections 6.1 and
6.2, GRELAN shall be responsible for paying all such costs described in this
Section 6.4.

            6.5 Provision of Know-How. As soon as practicable after the
Effective Date, and on a regular basis thereafter during the term of this
Agreement, each of BIONUMERIK and GRELAN will, subject to the confidentiality
and other limitations contained herein, provide its Know-How and will thereafter
provide its Improvements to KI PHARMA (and GRELAN as well in the case where
BIONUMERIK will provide such Know-How and Improvements) for the purpose of
enabling GRELAN and KI PHARMA to conduct the studies described in Sections 6.1
and 6.2, and otherwise to support Government Regulatory Approvals and the
marketing of Venture Products in the Territory in accordance with the terms of
this Agreement.

                                       14
<PAGE>
7.    MANUFACTURING RIGHTS FOR VENTURE PRODUCTS AND PURCHASE OF
      APPROVED PRODUCTS BY THE VENTURE.

            7.1 Manufacturing Rights for Venture Products BN.

                   7.1.1  BIONUMERIK will retain all manufacturing rights for
Venture Products BN. Any other terms and conditions regarding the sale or
provision of Venture Products BN by BIONUMERIK to KI PHARMA or a designated
third party will be separately agreed by the parties hereto after taking into
account the scenarios and illustrations contained on Attachment C hereto and the
other factors and considerations described in this Section. BIONUMERIK has the
right to manufacture Venture Products BN directly or to establish a contract
with a third party manufacturer to supply KI PHARMA or the designated third
party licensee for product distribution in the Territory. GRELAN shall help
BIONUMERIK to identify and recommend key qualified GMP manufacturers) in the
Territory who would be appropriate as such manufacturer. Upon receiving the
appropriate Government Regulatory Approvals for any Venture Products BN, KI
PHARMA (or if agreed to by the parties hereto, a KI PHARMA subsidiary or
affiliate or a designated third party) will directly purchase Venture Products
BN from BIONUMERIK at a specified sales price (the "BioNumerik Sales Price") in
accordance with the Supply Arrangements referred to in Section 7.4. The
BioNumerik Sales Price will be decided by the parties hereto in good faith
taking into account the following factors and considerations:

                   (a) [**];

                   (b) [**];

                   (c) [**];

                   (d) [**]; and

                   (e) [**].

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       15
<PAGE>

                  7.1.2 The estimated additional profit margin referred to in
Section 7.1.1 (e) will be divided [**] and distributed to BIONUMERIK and GRELAN.
The BioNumerik Sales Price to be decided by the parties will include:

                  (a) The total manufacturing price referred to in Section 7.1.1
(b); and

                  (b) [**] of the estimated additional profit margin referred to
in Section 7.1.1 (e).

            7.2 Manufacturing Rights for Venture Products GR.

                  7.2.1 GRELAN will retain all manufacturing rights for Venture
Products GR. Any other terms and conditions regarding the sale or provision of
Venture Products GR by GRELAN to KI PHARMA will be separately agreed by the
parties hereto after taking into account the scenarios and illustrations
contained on Attachment C hereto and the other factors and considerations
described in this Section. GRELAN has the right to manufacture Venture Products
GR directly or to establish a contract with a third party manufacturer to supply
KI PHARMA or the designated third party licensee for product distribution in the
Territory. Upon receiving the appropriate Government Regulatory Approvals for
any Venture Products GR, KI PHARMA (or if agreed to by the parties hereto, a KI
PHARMA subsidiary or affiliate or a designated third party) will directly
purchase Venture Products GR from GRELAN at a specified sales price (the "Grelan
Sales Price") in accordance with the Supply Arrangements referred to in Section
7.4. The Grelan Sales Price will be decided by the parties hereto in good faith
taking into account the following factors and considerations:

                   (a) [**];

                   (b) [**];

                   (c) [**];

                   (d) [**]

                   (e) [**].

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       16
<PAGE>
                   7.2.2 The estimated additional profit margin referred to in
Section 7.2.1(e) will be divided evenly (50:50) and distributed to BIONUMERIK
and GRELAN. The Grelan Sales Price to be decided by the parties will include:

                   (a) the total manufacturing price referred to in Section
7.2.1 (b); and

                   (b) [**] of the estimated additional profit margin referred
to in Section 7.2.1.

             7.3   Distribution and Sale of Venture Products.

             Based on the foregoing considerations, Venture Products will be
distributed and sold through one or more of the following methods:

                   (a) The Venture Products are licensed to a third party for
distribution and sale in the Territory;

                   (b) The Venture Products are licensed, distributed and sold
through a subsidiary or affiliate of KI PHARMA for distribution and sale in the
Territory; and

                   (c) Combinations of (a) and (b) above.

Examples of reasonable expected ranges for the pricing and sales prices for
drugs in Japan and scenarios to illustrate this pricing in relation to
hypothetical sales of Venture Products are included on Attachment C hereto.

             7.4 Commercial Supply Arrangements. Within [**] months prior to the
estimated time of the first commercial sale of a particular Venture Product in
the Territory, GRELAN (if such product is a Venture Product GR) or BIONUMERIK
(if such product is a Venture Product BN) shall enter into a commercial supply
agreement or make other appropriate arrangements (the "Supply Arrangements ")
with KI PHARMA to be negotiated in good faith by KI PHARMA, BIONUMERIK and
GRELAN and to reflect such terms and conditions as shall be reasonably necessary
to provide adequate supply of such Venture Product for sale and distribution in
the Territory.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       17
<PAGE>
          7.5 Product Labeling. Unless otherwise agreed to by GRELAN, all
labeling for Venture Products GR shall recognize that such products are
distributed under license from GRELAN. Unless otherwise agreed to by BIONUMERIK,
all labeling for Venture Products BN shall recognize that such products are
distributed under license from BIONUMERIK. One or more of KI PHARMA, GRELAN and
BIONUMERIK may be named on labeling for specified Venture Products as may be
agreed from time to time by all the parties hereto.

      8. STEERING COMMITTEE.

             8.1 Formation and Composition. Promptly following the Effective
Date, a Steering Committee of KI PHARMA will be established with responsibility
for the overall management of the development, manufacture, licensing
activities, distribution and marketing of the Venture Products in the Territory
in accordance with the terms of this Agreement. The Steering Committee shall be
comprised of two members, one appointed by GRELAN and one appointed by
BIONUMERIK, both of whom shall be cochairmen of the Steering Committee and
"Managers" of KI PHARMA (as defined in the Operating Agreement). Each Steering
Committee member should be a senior qualified full-time employee who serves as a
manager for his respective company and who has extensive knowledge of
pharmaceutical operations. [**] will be the founding Steering Committee members
who will co-chair the Steering Committee.

             8.2 Duties. The Steering Committee shall have such duties and
responsibilities as are provided in the Operating Agreement. No Steering
Committee member shall be removed and no new Steering Committee member shall be
appointed unless such removal or appointment is consented to by both GRELAN and
BIONUMERIK.

             8.3 Meetings. The Steering Committee will meet at least quarterly
(in Japan, U.S. or by telephone, video conference or internet - by mutual
consent) to review the progress of the development of Venture Products in the
Territory.

             8.4 Recommendation Regarding Management. The Steering Committee
will recommend management and key personnel to KI PHARMA for development,
manufacturing, regulatory, marketing, distribution and sale of Venture Products
in the Territory, at their request.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       18
<PAGE>
            8.5 Identification of Consultants. If needed, the Steering Committee
shall identify third party consultants and contractors to assist in the
development of the Venture Products in the Territory.

      9. DEVELOPMENT AND COMMERCIALIZATION PLAN.

            9.1 General Diligence Efforts. The parties hereto agree to use their
best efforts to commercialize or cause to be commercialized the Venture Products
in the Territory as soon as reasonably practicable.

            9.2 Target Development and Commercialization Plan. In addition to
the above general diligence requirements, KI PHARMA shall meet the target
development and commercialization plan for Venture Products. The target
development and commercialization plan for the BNP7787 Products is set forth in
Attachment D hereto, and those for the other Venture Products shall be decided
by the parties hereto as soon as reasonably practical. These target development
and commercialization plans will be updated on a semi-annual basis by the
Steering Committee. If any of the specified targets are not met with respect to
a particular Venture Product, and such targets continue to remain unmet for a
period of 60 days or greater following notice to the parties by any party
hereunder, then the parties hereto shall discuss and decide in good faith how to
solve the problem. If (a) the specified development performance targets as
defined by the Steering Committee for any particular Venture Product are not met
on an annual basis for three consecutive years, or (b) such product does not
receive Government Regulatory Approval to sell and distribute such product in
the Territory within 10 years of the date of this Agreement or conveyance of a
product to the Venture, then all licenses granted hereunder to such Venture
Product, and to the Improvements, Patent Rights, and Know-How provided by GRELAN
or BIONUMERIK with respect to such product shall terminate, and all right,
title, and interest in such Venture Product shall revert to the party or parties
who granted such rights to the Venture Product(s), provided that such rights
shall not revert to a party if the failure to meet such target was caused in
substantial part by the actions or failure to act of such party. An extension of
the time to meet the development performance requirements in the previous
sentence may be granted upon mutual agreement between GRELAN and BIONUMERIK.

      10. PATENT MATTERS.

             10.1 BioNumerik Patent Maintenance. BIONUMERIK will be responsible
for prosecuting and maintaining Patents for Venture Products BN at its own
expense and BIONUMERIK will own all Patent Rights for Venture Products BN.
BIONUMERIK shall advise GRELAN as to the progress of its patent applications and
registrations in Japan relating to Venture Products BN from time to time. In
addition, BIONUMERIK will advise GRELAN as to patent strategy and prosecution
outside the Territory with respect to Venture Products BN.

                                       19
<PAGE>
             10.2. GRELAN Patent Maintenance and Assistance. GRELAN will be
responsible for prosecuting and maintaining Patents for Venture Products GR at
its own expense and GRELAN will own all Patent Rights for Venture Products GR.
GRELAN shall advise BIONUMERIK as to the progress of its patent applications and
registrations in Japan relating to the Venture Products GR from time to time. In
addition, GRELAN will advise BIONUMERIK as to patent strategy and prosecution in
the Territory with respect to Venture Products BN.

              10.3. No Present Notification of Infringement-BioNumerik. Except
as described in Attachment E hereto, BIONUMERIK represents and warrants to KI
PHARMA and GRELAN that BIONUMERIK has not received any notification of, and has
no knowledge that the use by KI PHARMA and GRELAN of the Know-How or the
manufacture, use or sale of the Venture Products BN infringes any third party
patent rights in the Territory. If during the term of this Agreement an
infringement action should be brought in the Territory by a third party against
KI PHARMA or GRELAN or their Affiliates or sublicensees claiming that the use of
the Know-How or the Improvement relating to the Venture Products BN or the
manufacture, use or sale of the Venture Products BN licensed hereunder infringes
any patent rights of the third party in the Territory, KI PHARMA and/or GRELAN
will promptly inform BIONUMERIK of such fact in writing and BIONUMERIK agrees to
consult with KI PHARMA and GRELAN in order to decide together the course of
action which should be taken in such case. Each of the parties hereto agrees to
cooperate fully in any defense against such infringement action. All legal
expenses and costs (including attorneys' fee) in such defense shall be borne
[**] by BIONUMERIK and [**] by GRELAN.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       20

<PAGE>

            10.4. No Present Notification of Infringement- Grelan. Except as
described in Attachment E hereto, GRELAN represents and warrants to KI PHARMA
and BIONUMERIK that GRELAN has not received any notification of, and has no
knowledge that the use by KI PHARMA and GRELAN of the Know-How or the
manufacture, use or sale of the Venture Products GR infringes any third party
patent rights in the Territory. If during the term of this Agreement an
infringement action should be brought in the Territory by a third party against
KI PHARMA or GRELAN or their Affiliates or sublicensees claiming that the use of
the Know-How or the Improvement relating to the Venture Products GR or the
manufacture, use or sale of the Venture Products GR licensed hereunder infringes
any patent rights of the third party in the Territory, KI PHARMA and/or GRELAN
will promptly inform BIONUMERIK of such fact in writing and GRELAN agrees to
consult with KI PHARMA and BIONUMERIK in order to decide together the course of
action which should be taken in such case. Each of the parties hereto agrees to
cooperate fully in any defense against such infringement action. All legal
expenses and costs (including attorneys' fee) in such defense shall be borne
[**] by BIONUMERIK and [**] by GRELAN.

            10.5. Enforcement of Patents and Proprietary Rights.

                  (a)   If allowable by law, KI PHARMA, as exclusive licensee
for the Venture Products in the Territory, shall have power to institute and
prosecute proceedings or suits ("Suits") for

infringement of the Patent Rights and/or Patents and proprietary rights
regarding Venture Products in the Territory. BIONUMERIK may join and, if
required by law, BIONUMERIK will join as party plaintiff in such Suits regarding
Venture Products BN. In addition, KI PHARMA shall not institute or settle any
Suit regarding Venture Products BN without the consent of BIONUMERIK (which
consent will not be unreasonably withheld) and BIONUMERIK may assume control of
any Suit regarding Venture Products BN at its own expense by giving notice to KI
PHARMA and agreeing to be responsible for all further costs of such Suit. GRELAN
may join and, if required by law, GRELAN will join as party plaintiff in such
Suits regarding Venture Products GR. In addition, KI PHARMA shall not institute
or settle any Suit regarding Venture Products GR without the consent of GRELAN
(which consent will not be unreasonably withheld) and GRELAN may assume control
of any Suit regarding Venture Products GR at its own expense by giving notice to
KI PHARMA and agreeing to be responsible for all further costs of such Suit.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       21
<PAGE>
                  (b)   Except as otherwise expressly provided herein, all legal
expenses and costs (including attorneys' fee) in such Suits and all other
third-party patent litigation regarding the Venture Products in the Territory
(the "Legal Expenses") will be borne 50% by GRELAN and 50% by BIONUMERIK.

                  (c)   All recoveries in any Suit (including attorneys' fee)
and all other third-party patent litigation regarding the Venture Products in
the Territory (regardless of which party actually receives such recovery) shall
be applied first in or toward satisfaction of all expenses borne by GRELAN and
BIONUMERIK in connection with such Suit or other patent litigation. If any
surplus remains it shall (i) be paid in full to BIONUMERIK if the Suit or other
patent litigation is related to Venture Products BN or (2) be paid in full to
GR-ELAN if the Suit or other patent litigation is related to Venture Products
GR.

                  (d)   KI PHARMA shall give BIONUMERIK and GRELAN full and
complete access to all information BIONUMERIK or GRELAN reasonably request
related to the Suits.

      11.   IMPROVEMENTS.

            11.1  BioNumerik Improvements Included. Following the Effective Date
and during the term of this Agreement, without any further payment, BIONUMERIK
shall promptly and fully disclose and grant (a) an exclusive royalty-free
license to KI PHARMA to use any BioNumerik Improvements in the Territory for the
purpose of development and commercialization of the Venture Products in the
Territory

in accordance of this Agreement, and (b) a non-exclusive royalty free license to
GRELAN to use such Improvements in the Territory for the purpose of development
of Venture Products in the Territory in accordance with this Agreement. In
addition, BIONUMERIK hereby grants GRELAN effective as of the Effective Date (a)
a non-exclusive, perpetual, fully paid-up royalty-free license, with the right
to sublicense, to use all BioNumerik Improvements related only to Venture
Products GR outside the Territory for the purpose of development and
commercialization of such products outside the Territory, and (b) a
nonexclusive, perpetual (but only after the expiration or termination of this
Agreement), fully paid-up royaltyfree license, with the right to sublicense, to
use such BioNumerik Improvements related only to Venture Products GR in the
Territory for the purpose of development and commercialization of such products
in the Territory.

                                       22
<PAGE>
            11.2. Grelan Improvements Included. Following the Effective Date and
during the term of this Agreement, without any further payment, GRELAN shall
promptly and fully disclose and grant an exclusive royalty-free license to KI
PHARMA to use any Grelan Improvements in the Territory for the purpose of
development and commercialization of Venture Products in the Territory in
accordance with this Agreement. In addition, GRELAN hereby grants to BIONUMERIK
effective as of the Effective Date (a) a non-exclusive, perpetual, fully paid-up
royalty-free license, with the right to sublicense, to use all Grelan
Improvements related only to Venture Products BN outside the Territory for the
purpose of development and commercialization of such products outside the
Territory and (b) a non-exclusive, perpetual (but only after the expiration or
termination of this Agreement), fully paid-up royalty-free license, with the
right to sublicense, to use such Grelan Improvements related only to Venture
Products BN in the Territory for the purpose of development and
commercialization of such products in the Territory.

            11.3. Joint Improvements. Any new intellectual property generated by
KI PHARMA shall be jointly owned by BIONUMERIK and GRELAN on an equal basis.
Each of BIONUMERIK and GRELAN hereby agrees to license its interest in such
intellectual property in the manner provided in Sections 11.1 and 11.2.

            11.4. Sublicense of Improvements. The sublicense by KI PHARMA of the
rights to any BioNumerik Improvements in the Territory shall require the written
prior approval of BIONUMERIK, and the sublicense by KI PHARMA of the rights to
any Grelan Improvements in the Territory shall require the written prior
approval of GRELAN.

                                       23
<PAGE>
      12.   TRADEMARKS AND TRADEMARK RIGHTS.

            12.1. KI PHARMA shall register and maintain the Trademarks for the
benefit and at the expense of KI PHARMA for use in and association with Venture
Products in the Territory. GRELAN agrees to assist in such registration, if
requested by KI PHARMA or BIONUMERIK. KI PHARMA shall sell the Venture Products
only under the Trademarks.

            12.2. GRELAN shall be the exclusive owner of all Trademarks and
trademark registrations associated with Venture Products GR, and BIONUMERIK
shall be the exclusive owner of all Trademarks and trademark registrations
associated with Venture Products BN. GRELAN shall remain free to use and grant
rights to the use of the Trademarks outside of the Territory with respect to
Venture Products GR. BIONUMERIK shall remain free to use and grant rights to the
use of the Trademarks outside of the Territory with respect to Venture Products
BN.

            12.3. KI PHARMA shall maintain the quality control standards set
forth by GRELAN and BIONUMERIK from time to time with respect to the Trademarks;
and KI PHARMA will ensure that any Sublicensee using the Trademarks in the
Territory shall be subject to similar standards of quality control.

      13.   CONFIDENTIALITY.

            13.1. Confidential and Proprietary Information. Each party hereto
acknowledges that in order for the parties to carry out their respective
obligations under this Agreement, it may be necessary for the parties to
disclose to each other certain Confidential Information. Each party hereto
agrees:

                  13.1.1. To ensure that it does not reveal or make available to
any third party any Confidential Information of any other party, except as such
disclosure may be expressly authorized by this Agreement or otherwise
specifically approved in writing by the party against whom such disclosure is
sought and to ensure that it will treat such Confidential Information of each
other party in the same manner as it treats its own Confidential Information,
such treatment to be at least the degree that a reasonable person would perform
under similar circumstances;

                                       24
<PAGE>
                  13.1.2. To ensure that Affiliates, sublicensees, employees,
agents, associates or other persons to whom such disclosure may be made or who
may otherwise have access to such Confidential Information of any other party
have agreed in writing to safeguard and maintain such Confidential Information
of the other party or parties in confidence;

                  13.1.3. To ensure that Confidential Information of the other
party or parties is not used for the receiving party's benefit except as such
benefits are expressly contemplated herein;

                  13.1.4. To prohibit the Confidential Information of the other
party or parties from being duplicated in any manner; except as is reasonably
necessary to perform the tasks and obligations contemplated under this
Agreement; and

                  13.1.5. To prohibit the Confidential Information of the other
party or parties from being published in any form without the express written
consent of the disclosing party.

            13.2. Matters not Included as Confidential Information.
Notwithstanding anything herein to the contrary, the defined term "Confidential
Information" and the obligations of nondisclosure, nonuse and confidentiality
relating thereto shall not include any information or data which:

                  13.2.1. Is or becomes known to the general public through no
action or fault of the receiving party;

                  13.2.2. Was already known to the receiving party prior to the
date of disclosure hereunder, as evidenced by the written records of that party,
without any obligation of confidentiality;

                  13.2.3. Is or becomes known to the receiving party without any
obligation of confidentiality from a third party having the right to disclose
the same, and not having a confidential relationship with the disclosing party
with respect thereto; or

                  13.2.4. Is necessary for the receiving party or its Affiliates
to disclose to a governmental authority or any agency thereof on a
non-confidential basis, in order to pursue Government Regulatory Approvals or
other regulatory approvals as contemplated by this Agreement or for other

                                       25
<PAGE>
purposes related to the intent of this Agreement; provided, however, that the
receiving party shall notify the disclosing party before disclosing such
Confidential Information.

            13.3. Survival of Confidentiality. The obligations of this Section
13 with respect to Confidential Information shall continue during the term of
this Agreement and for 10 years after the termination or expiration of this
Agreement.

      14.   PROVISION FOR VENTURE FUNDING.

      GRELAN and BIONUMERIK shall provide KI PHARMA with reasonable funding in
proportion to their ownership interest in KI PHARMA immediately before such
funding so that KI PHARMA is adequately funded for its ongoing business and
taxes. Such funding shall be provided or obtained in such form and in such
manner as may be agreed between GRELAN and BIONUMERIK, but for the avoidance of
doubt, may include contribution of additional capital, member loans or member
guarantees for borrowing from third parties. GRELAN will be responsible for
bearing the ongoing operating costs for KI PHARMA (up to a maximum of [**] until
the time that product revenues are obtained for the Venture Products.

      15.   ACCOUNTING.

            KI PHARMA shall keep and shall cause its Sublicensees to keep
written (English) records and reports relating to the transactions covered by
this Agreement. As soon as practicable after the end of each fiscal year of KI
PHARMA, and in any event within 60 days thereafter, KI PHARMA shall prepare or
cause to be prepared, audited financial statements of KI PHARMA as of the end of
and for such fiscal year, including balance sheets, statements of operations,
and statements of cash flow, all of which will be prepared in accordance with
generally accepted accounting principles consistently applied during the periods
covered thereby and setting forth in each case in comparative form the figures
for the previous fiscal year, all in reasonable detail and audited by
independent public accountants of internationally recognized standing selected
by KI PHARMA, BIONUMERIK, and GRELAN. As soon as practicable after the end of
the first, second, and third quarterly accounting periods in each fiscal year of
KI PHARMA and in any event within

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       26
<PAGE>
30 days thereafter, KI PHARMA shall prepare or cause to be prepared, a balance
sheet of KI PHARMA as of the end of each such quarterly period, and statements
or operations and statements of cash flow of KI PHARMA, for such period and for
the current fiscal year to date, prepared in accordance with generally accepted
accounting principles consistently applied during the periods covered thereby
(other than for accompanying notes), subject to changes resulting from year-end
audit adjustments, and setting forth in each case the comparative figures for
the previous fiscal year, all in reasonable detail. All such prepared
documentation referred to herein will be provided by KI PHARMA to BIONUMERIK and
GRELAN without charge. Upon the request of either BIONUMERIK or GRELAN, and on
reasonable notice, KI PHARMA shall and shall cause its Affiliates and
Sublicensees to permit, at the expense of the requesting party (BIONUMERIK or
GRELAN, as the case may be), an independent certified public accountant
reasonably acceptable to KI PHARMA and the requesting party, to have access
during reasonable business hours to such records as may be necessary to (a)
obtain any additional information and records as may be required to prepare
audited financial information for KI PHARMA or as may be otherwise required to
comply with financial reporting and disclosure requirements of such party, and
(b) determine the correctness of any fee or payment statements and actual
payments made under this Agreement. Each of BIONUMERIK and GRELAN undertakes and
agrees that neither BIONUMERIK nor GRELAN nor any certified public accountant
selected by either of them pursuant to this Section shall disclose any
information so obtained except as required by law or to the extent necessary to
enforce this Agreement.

      16.   USE OF NAMES. The parties hereto understand that each of BIONUMERIK,
GRELAN, and KI PHARMA may disclose certain matters pertaining to this Agreement
which may include the names of KI PHARMA, GRELAN and BIONUMERIK, and the subject
matter of this Agreement, if and to the extent that such disclosure is required
by the applicable securities laws or other applicable laws and regulations;
provided, however, that if such disclosure is made in the form of public
statements, whether oral or written, including, but not limited to, shareholder
reports, communications with stock market analysts, press releases or other
communications with the media, the disclosing party must obtain the prior
written approval of the other parties (which approval shall not be unreasonably
withheld) and further provided that no incorrect, exaggerated or misleading
statements shall be disclosed.

                                       27
<PAGE>
      17.   INDEMNIFICATION.

            17.1. BioNumerik Indemnification. BIONUMERIK agrees to defend,
indemnify and hold harmless GRELAN and KI PHARMA from and against any and all
(a) product liability and related costs and expenses (including attorney fees)
arising out of Venture Products BN supplied by BIONUMERIK and (b) all other
claims, damages or costs, including attorney fees, arising out of manufacturing
defects of any Venture Products supplied by BIONUMERIK, or the negligence,
failure to follow established good manufacturing practices or International
Conference on Harmonization (ICH) guidelines, or non-compliance with applicable
laws and regulations in the Territory on the part of BIONUMERIK.

            17.2. Grelan Indemnification. GRELAN agrees to defend, indemnify and
hold harmless BIONUMERIK and KI PHARMA from and against any and all (a) product
liability and related costs and expenses (including attorney fees) arising out
of Venture Products GR supplied by GRELAN and (b) all other claims, damages or
costs, including attorney fees, arising out of manufacturing defects of any
Venture Products supplied by GRELAN, or the negligence, failure to follow
established good manufacturing practices or ICH guidelines, or non-compliance
with applicable laws and regulations in the Territory on the part of GRELAN.

            17.3. KI Pharma Indemnification. Notwithstanding the provisions of
Sections 17.1 and 17.2, KI PHARMA shall defend, indemnify and hold harmless
BIONUMERIK and GRELAN from and against any and all third party related claims,
damages or costs including attorney fees arising out of the failure by KI PHARMA
to distribute the Venture Products manufactured by BIONUMERIK or GRELAN in
accordance with applicable legal and regulatory requirements, the negligence of
KI PHARMA with respect to the Venture Products, or the non-compliance by KI
PHARMA with applicable laws and regulations in the Territory.

                                       28
<PAGE>
      18.   DURATION AND TERMINATION OF AGREEMENT.

            18.1  Duration.

                  18.1.1(a) Unless otherwise terminated as set forth below, this
Agreement shall terminate upon the earlier to occur of (i) such time following
commercialization of the Venture Products, that Venture Products are no longer
being sold and/or distributed by KI PHARMA or its Sublicensees in the Territory
and (ii) 25 years after the effective date hereof.

                  18.1.1(b) This Agreement shall also immediately terminate if
the Effective Date does not occur within three months after the date of this
Agreement. In the event of termination pursuant to this Section 18.1.1(b), the
obligations and rights of the parties under this Agreement shall terminate,
except that the confidentiality obligations under Section 13 shall survive and
continue, and the rights and obligations under Section 17 and Section 22.12
shall survive and continue.

            18.2  Termination.

                  18.2.1. The parties hereto shall be able to terminate this
Agreement in the following events:

                        (a)   If a party to this Agreement shall materially
breach, materially default or otherwise materially fail to perform under the
terms of this Agreement or the Operating Agreement or any material
representation or warranty made by such party herein proves to have been
incorrect or misleading in any material respect when made, the other party or
parties may terminate this Agreement by giving 60 days advance written notice,
unless the breach, default or failure is cured within such notice period.

                        (b)   If GRELAN or BIONUMERIK shall become bankrupt or
insolvent or any proceeding is commenced to place its business in the hands of a
receiver, assignee or trustee in bankruptcy, or any proceeding is commenced for
company reorganization (kaisha kosei), arrangement (seiri), civil rehabilitation
(minjisaisei), dissolution (kaisan) and liquidation (seisan), whether
voluntarily or otherwise, and such proceedings are not dismissed within ninety
(90) days of the commencement of any such proceeding, then the party that is not
bankrupt, insolvent or subject to such proceeding may terminate this Agreement
upon 30 days advance written notice.

                                       29
<PAGE>
                        (c)   If, following the Effective Date, KI PHARMA is
dissolved, either GRELAN or BIONUMERIK may terminate this Agreement upon 30 days
advance written notice.

                        (d)   If a third party Competitor (defined below)
acquires a Controlling Interest (defined below) in GRELAN, then BIONUMERIK may
terminate this Agreement by giving 60 days advance written notice.

                        (e)   If a third party Competitor (defined below)
acquires a Controlling Interest (defined below) in BIONUMERIK, then GRELAN may
terminate this Agreement by giving 60 days advance written notice.

                        (f)   For purposes hereof, "Competitor" shall mean a
company or organization engaged in the business of discovering, developing,
manufacturing and/or selling any products or services that directly compete
with any of the Venture Products or any of the other material products which
the party who has the right to terminate this Agreement under this Section 18.2
is then developing manufacturing, selling or having sold in the Territory.

                        (g)   For purposes hereof, "Controlling Interest" shall
mean (a) the ownership, whether directly or indirectly, of a majority of the
voting stock or equity interests, or substantially all of the assets or business
of a party, or (b) the ability, whether directly or indirectly, to appoint a
majority of the directors or other governing body of a party.

            18.3. Effect of Expiration or Termination. Termination is not the
sole remedy under this Agreement and termination of this Agreement for any
reason or the expiration of this Agreement shall not affect obligations or
rights of any party incurred or accrued prior to such termination or expiration.
The termination of this Agreement shall not affect the right of any party to
recover damages from any breach of this Agreement.

                                       30
<PAGE>
                  18.3.1 In the event of the expiration of this Agreement
pursuant to Section 18.1.1(a), or in the event of a valid termination of this
Agreement by either GRELAN or BIONUMERIK pursuant to Section 18.2.1 (c) or by KI
PHARMA pursuant to Section 18.2.1(a), the obligations and rights of the parties
under this Agreement shall terminate, except that the confidentiality
obligations under Section 13 shall survive and continue, the ownership and the
rights granted under Section 6.2.2 with respect to the Data and Results
resulting or obtained prior to such expiration or termination shall survive and
continue, the perpetual rights granted under Section 11 with respect to the
Improvements and KI PHARMA's new intellectual property resulting or obtained
prior to the expiration or termination shall survive and continue, and the
rights and obligations under Section 17 and Section 22.12 shall survive and
continue.

                  18.3.2 In the event of a valid termination of this Agreement
by GRELAN pursuant to Section 18.2.1(a), Section 18.2.1(b), or Section
18.2.1(e), then notwithstanding any provisions contrary to this Section 18.3.2,
(i) all licenses granted hereunder (whether contingent or perpetual) to the
Venture Products GR, and to the Grelan Improvements, Grelan Patent Rights, and
Know-How provided by GRELAN shall terminate, (ii) all licenses granted hereunder
(whether contingent or perpetual) to the Venture Products BN, and to the
BioNumerik Improvements, BioNumerik Patent Rights, and Know-How provided by
BIONUMERIK shall survive and continue without being affected, except that any
such licenses which are stated to be exclusive shall become non-exclusive after
such termination and the amounts of Upfront Payment and Royalties payable by KI
PHARMA for such products shall be reasonably adjusted as may be agreed to by the
parties hereto in good faith, and (iii) all rights, title and interest in the
Venture Products GR shall revert to GRELAN. For the avoidance of doubt, GRELAN
and BIONUMERIK shall retain the right to use the Data and Results as provided in
Section 6.2.2.

                  18.3.3. In the event of a valid termination of this Agreement
by BIONUMERIK pursuant to Section 18.2.1(a), Section 18.2.1(b), or Section
18.2.1(d), then notwithstanding any provisions contrary to this Section 18.3.3,
(i) all licenses granted hereunder (whether contingent or perpetual) to the
Venture Products BN, and to the BioNumerik Improvements, BioNumerik Patent
Rights, and Know-How provided by BIONUMERIK shall terminate, (ii) all licenses
granted hereunder (whether contingent or perpetual) to the Venture Products GR,
and to the Grelan Improvements, Grelan Patent Rights, and Know-How provided by
GRELAN shall survive and continue without being affected, except that any such
licenses which are stated to be exclusive shall become non-exclusive after such
termination and the amounts of Up-front Payment and Royalties payable by KI
PHARMA for such products shall be reasonably adjusted as may be agreed to by the
parties hereto in good faith, and (iii) all rights, title and interest in the

                                       31
<PAGE>
Venture Products BN shall revert to BIONUMERIK. For the avoidance of doubt,
BIONUMERIK and GRELAN shall retain the right to use the Data and Results as
provided in Section 6.2.2.

      19.   BIONUMERIK REPRESENTATIONS & WARRANTIES.

            19.1  Due Organization and Authority. BIONUMERIK represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of the State of Texas and has the corporate power
and authority to execute, deliver and carry out the terms and provisions of this
Agreement; (ii) that the execution, delivery and performance of this Agreement
by BIONUMERIK shall not require the consent of any third party (other than any
shareholder consents to be obtained prior to the Effective Date), and shall not
cause a breach or violation under any fiduciary, contractual, statutory or
judicial obligation or restraint to which BIONUMERIK is subject or bound; (iii)
that the person executing this Agreement on behalf of BIONUMERIK is duly
authorized to do so to bind the corporation, and (iv) that attached hereto as
Attachment F are audited Financial Statements of BIONUMERIK at and for the year
ended March 31, 2000, which Financial Statements are true and correct in all
material respects.

            19.2  Safety of Product(s). BIONUMERIK represents and warrants that
it has not received any notification of, and has no knowledge that there is now
pending or that there have been any United States judicial or administrative
orders to ban the development or use of any Venture Products BN and that
BIONUMERIK has no knowledge of any adverse reactions or test results encountered
or discovered regarding the use of any Venture Products BN which would render
such products unsuitable or unsafe for the purpose contemplated by this
Agreement, that have not been disclosed to GRELAN.

            19.3  No Pending Action Against BioNumerik. BIONUMERIK represents
and warrants that to its knowledge there is no action or proceeding pending
against BIONUMERIK relating to the Venture Products BN, and to its knowledge
there is no basis for or threat of any action or proceeding relating to the
Venture Products BN, which might result in a material adverse change in the
business or financial condition of BIONUMERIK which could adversely affect the
rights of GRELAN and KI PHARMA under this Agreement or the development of the
Venture Products.

                                       32
<PAGE>
      20.   GRELAN REPRESENTATIONS AND WARRANTIES.

            20.1  Due Organization and Authority. GRELAN represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of Japan and has the corporate power and authority
to execute, deliver and carry out the terms and provisions of this Agreement;
(ii) that the execution, delivery and performance of this Agreement by GR-ELAN
shall not require the consent of any third party and shall not cause a breach or
violation under any fiduciary, contractual, statutory or judicial obligation or
restraint to which GRELAN is subject or bound; and (iii) that the person
executing this Agreement on behalf of GRELAN is duly authorized to do so to bind
GRELAN.

            20.2  Safety of Product(s). GRELAN represents and warrants that it
has not received any notification of, and has no knowledge that there is now
pending or that there have been any Japan judicial or administrative orders to
ban the development or use of any Venture Products GR and that GRELAN has no
knowledge of any adverse reactions or test results encountered or discovered
regarding the use of any Venture Products GR which would render such products
unsuitable or unsafe for the purpose contemplated by this Agreement, which have
not been disclosed to BIONUMERIK.

            20.3  No Pending Action Against Grelan. GRELAN represents and
warrants that to its knowledge there is no action or proceeding pending against
GRELAN relating to the Venture Products GR, and to its knowledge there is no
basis for or threat of any action or proceeding relating to the Venture Products
GR, which might result in a material adverse change in the business or financial
condition of GRELAN which could adversely affect the rights of BIONUMERIK or KI
PHARMA under this Agreement or the development of the Venture Products.

      21.   ASSIGNMENTS.

            21.1  Assignment Restrictions. Subject to Sections 21.2 and 21.3
below and excluding the sublicense rights expressly granted herein, no party
shall have the right to assign or delegate this Agreement, or any of its rights
or obligations under this Agreement without the express written consent of the
other parties, such consent not to be unreasonably withheld, and said assignment
or delegation without such consent shall be null and void for all purposes.

                                       33
<PAGE>
            21.2  Sale of Business. BIONUMERIK or GRELAN may assign its entire
interest in this Agreement to a third party other than a Competitor; provided
that (i) such assignment is part of the sale of all or substantially all of the
assignor's business related to the Venture Products; (ii) the ownership in all
Know-How, Patent Rights, Improvements and Trademarks of the assignor and all
interest of the assignor in KI PHARMA are assigned to such third party
simultaneously and are subject to any additional obligations contained in the
Operating Agreement; (iii) notice of any contemplated assignment is given to the
other party not less than 60 days prior to the effectiveness thereof; (iv)
following receipt of such notice, the assignor, if requested by the other party
and such assignment is contemplated to be made to a Competitor of the other
party, negotiates in good faith with the other party for a period of 40 days
with a view to finding a mutually satisfactory solution; and (v) the assignor
delivers to the other party a copy of the instrument, duly executed by the
parties thereto, effecting such assignment and affirming a complete assumption
by the assignee of the obligations of the assignor hereunder and a recognition
of the rights of the other party.

            21.3  Assignment to Affiliates. This Agreement and the rights and
obligations hereunder shall be assignable, in whole or in part, by BIONUMERIK,
without consent of GRELAN or KI PHARMA, to one or more Affiliates that is not a
Competitor of GRELAN or KI PHARMA and who shall affirm to GRELAN and KI PHARMA a
complete assumption of the obligations assigned; provided that BIONUMERIK shall
guarantee the performance by such Affiliates) of such obligations. This
Agreement and the rights and obligations hereunder shall be assignable, in whole
or in part, by GRELAN, without consent of BIONUMERIK or KI PHARMA, to one or
more Affiliates that is not a Competitor of BIONUMERIK or KI PHARMA and who
shall affirm to BIONUMERIK and KI PHARMA a complete assumption of the
obligations assigned; provided that GRELAN shall guarantee the performance by
such Affiliates) of such obligations.

      22.   MISCELLANEOUS.

            22.1  Regulatory Communications. Each party agrees to notify the
other parties immediately by telephone (with prompt written follow-up in
English) of any inquiry, contact or communication received from any governmental
regulatory agency or other official body which materially and adversely relates
to or impacts upon the Venture Products or any component or ingredient thereof,
and will promptly furnish the other parties with copies of all written
communications relating thereto sent to or received from said regulatory agency.

                                       34
<PAGE>
            22.2  Adverse Events. Each party shall promptly inform the other
parties in writing of any material side effects or adverse events, conditions or
reactions encountered by or reported to them in connection with the Venture
Products which could in any significant way render any of the Venture Products
or any of the components thereof unsafe or unfit.

            22.3  Liability Insurance. KI PHARMA will maintain liability
insurance in amounts that are appropriate to protect against liabilities arising
in connection with the Venture Products in the Territory. GRELAN shall be
responsible for reimbursing KI PHARMA or otherwise bearing the cost of such
insurance with respect to each Venture Product until the time that such product
receives marketing approval in the Territory. After such time, the cost of such
insurance for an approved product in the Territory shall be paid 50% by GRELAN
and 50% by BIONUMERIK.

            22.4  Litigation. KI PHARMA will bear the costs of all non-patent
litigation relating to KI PHARMA and the Venture Products. GRELAN and BIONUMERIK
will each be responsible for reimbursing KI PHARMA or otherwise bearing the cost
of 50% of such litigation costs. KI PHARMA will advise BIONUMERIK with respect
to litigation strategies and operations in the Territory.

            22.5  Auditors. The auditors of KI PHARMA will be Ernst & Young or
another internationally recognized accounting firm approved by KI PHARMA, GRELAN
and BIONUMERIK. The audit report of the auditors will be in English. Each of
GRELAN and BIONUMERIK may select an additional accounting or auditing firm to
review the books and records of KI PHARMA, and all associated costs for such
additional firm will be paid by the party selecting it.

            22.6  Marketing Analysis and Reports. KI PHARMA and/or GRELAN shall
provide such reports and analyses as BIONUMERIK may reasonably request
containing English translations describing the market for and performance of the
Venture Products in the Territory, the market position and promotion of the
Venture Products in the Territory, competitive product information including
pricing and promotional information, and physician and consumer acceptance of
the Venture Products developed or obtained by KI PHARMA and/or GRELAN which
could affect the Venture Products in the Territory or generally. To assist in
the distribution of Venture Products in the Territory, KI PHARMA and/or GRELAN
shall regularly provide BIONUMERIK with information and data which will enable
BIONUMERIK to have a complete understanding of the general and specific markets
relating to the sale of Venture Products in the Territory.

                                       35
<PAGE>
            22.7  Notice / Reports. Any reports, notices or other communications
required or permitted to be given by any party hereto will be given in writing
by personal delivery, courier service or facsimile, or by registered or
certified air mail, postage prepaid, return receipt requested, addressed to each
respective party at the address shown below.

                  If to BIONUMERIK:

                  BioNumerik Pharmaceuticals, Inc.
                  8122 Datapoint Drive, Suite 1250
                  San Antonio, Texas 78229
                  Attn: Frederick H. Hausheer, M.D.
                  Facsimile No.: (210) 614-0643

                  If to GRELAN:

                  Grelan Pharmaceutical Co., Ltd.
                  Ogura Bldg. 5F
                  Nihonbashi Kobunacho 6-6
                  Chuo-ku, Tokyo 103-0024
                  Japan
                  Attn: Hashime Kanazawa, Ph.D.
                  Facsimile No. (81) 3-3281-5980

or to such other address as any party may indicate by proper notice to the other
parties in the same manner as provided herein; provided, however, that the
notices and opinions referred to in or required under Sections 10 and 18 shall
be given by personal delivery, courier service or registered or certified
airmail as mentioned above. All notices are deemed effective on the date of
receipt or, if delivery is not accepted, five (5) days after placement with the
addressee, an overnight courier service or a post office, as applicable.

            22.8  Severability. Should any provision of this Agreement be held
to be invalid, unenforceable, or against public policy, the remaining provisions
hereof shall not be affected thereby. In such event, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible with respect to those provisions
which were held to be invalid, unenforceable or against public policy.

            22.9  Counterparts. This Agreement may be executed in several
counterparts, each of which will be an original, but all of which, when taken
together, will constitute one and the same instrument.

                                       36
<PAGE>
            22.10 Warranty Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN SECTIONS
19 AND 20, NEITHER BIONUMERIK NOR GRELAN MAKES ANY WARRANTY WITH RESPECT TO ANY
TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT
AND EACH OF BIONUMERIK AND GRELAN HEREBY DISCLAIMS WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH
RESPECT TO ANY AND ALL OF THE FOREGOING. THE PARTIES UNDERSTAND AND AGREE THAT
DEVELOPMENT AND COMMERCIALIZATION OF THE VENTURE PRODUCTS WILL INVOLVE APPROVAL
BY REGULATORY AUTHORITIES AND THAT NO PARTY IS GUARANTEEING THE SAFETY,
EFFICACY, MANUFACTURE OR REGULATORY APPROVAL OF ANY VENTURE PRODUCTS.

            22.11 Force Majeure.

                  22.11.1. Except for the payment of money, no failure or
omission by the parties hereto in the performance of any obligation of this
Agreement shall be deemed a breach of this Agreement nor create any liability,
if the same arises as a result of force majeure, i.e., any cause or causes
beyond the control of the parties, including, but not limited to the following,
which for the purposes of this Agreement, shall be regarded as beyond the
control of the party in question: acts of God; acts, omissions, rules,
regulations, or orders of any governmental authority or any officer, department,
agency or instrumentality thereof; fire; storm; flood; earthquake; accident;
acts of the public enemy; war; rebellion; insurrection; riot; invasion; strikes,
lockouts or shortages of raw materials or other supplies.

                  22.11.2. In the event of such cause intervening, such excuse
of performance shall be only to the extent that such non-performance is beyond
the reasonable control of the party bound by such covenant or obligation; and
the party so affected shall use its best efforts to eliminate or cure or
overcome any of such causes and to resume performance of its covenants and
obligations with all possible speed.

            22.12. Arbitration. All disputes, controversies or differences which
may arise among the parties, out of or in relation to or in connection with this
Agreement or the Operating Agreement, or the breach thereof, shall be finally
settled by arbitration, by the American Arbitration Association in Honolulu,
Hawaii, U.S.A., by a panel of three (3) arbitrators in accordance with the then
current American Arbitration Association International Arbitration Rules,
provided that the arbitrators will first render a preliminary

                                       37
<PAGE>
decision setting forth their grounds for decision and providing at least thirty
(30) days for each of the parties to respond. The parties hereto expressly waive
any right to appeal such decision or to challenge the decision in any court.
Judgment thereof may be entered in any court of competent jurisdiction in the
United States or Japan. This clause shall not be used to prohibit the right of
any party to seek injunctive relief in appropriate circumstances.

            22.13 Export Controls. The parties agree to abide by the United
States and Japanese laws and regulations governing exports of the Venture
Products or any other technology developed or disclosed as a result of this
Agreement. The parties acknowledge that any performance under this Agreement is
subject to any restrictions which may be imposed by the United States and
Japanese laws and regulations governing exports. Each party agrees to provide
the other parties with any assistance, including written assurances, which may
be required by a competent governmental authority and by applicable laws and
regulation as a precondition for any disclosure of technology by the other
parties under the terms of this Agreement. In addition, the parties hereto agree
to take all actions as may reasonably be required to assure compliance with all
applicable requirements of the U.S. Foreign Corrupt Practices Act.

            22.14 Construction / Jurisdiction / Official Language. This
Agreement shall be construed in accordance with the laws of the State of Texas,
U.S.A. Subject to the arbitration provisions contained in Section 22.12, each
party hereto hereby irrevocably consents and submits to the jurisdiction of the
Courts of the State of Texas and of the United States of America for all
purposes in connection with any proceeding which arises out of or relates to
this Agreement. English shall be the official language of this Agreement and any
related agreement provided for hereunder and all communications between the
parties hereto shall be conducted in that language. Each party recognizes that
the parties hereto grant no licenses, by implication or otherwise, except for
the licenses expressly set forth in this Agreement. GRELAN agrees to promptly
provide BIONUMERIK with written English translations of (a) all material
reports, financial statements, and documents relating to the Venture Products or
this Agreement that are in Japanese and (b) other documents that are in Japanese
and relate to the Venture Products or this Agreement as may be reasonably
requested by BIONUMERIK.

      23.   ENTIRE AGREEMENT. This Agreement comprises the entire understanding
and Agreement of the parties hereto with respect to the specific subject matter
of this Agreement, and supersedes all prior agreements or understandings,
written or oral, between the parties hereto with respect to the specific subject
matter of this Agreement. In addition, and except as otherwise expressly
provided

                                       38
<PAGE>
herein, those obligations under the existing confidentiality agreements,
materials transfer agreements, stock purchase agreements, and related agreements
between and among BIONUMERIK and GRELAN, and in certain cases certain third
parties, shall continue in full force and effect in accordance with their terms.
This Agreement may not be amended except by a written instrument signed by
GRELAN and BIONUMERIK.

      24.   CAPTIONS. The captions used in this Agreement are for purposes of
clarification only and are not meant to be construed as part of this Agreement.

      IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first written above.

GRELAN PHARMACEUTICAL CO., LTD.            BIONUMERIK PHARMACEUTICALS, INC.

By:   /s/ H. KANAZAWA                      By:   /s/ FREDERICK H. HAUSHEER, M.D.
   --------------------------------------     ----------------------------------
      Hashime Kanazawa, Ph.D.                    Frederick H. Hausheer, M.D.
      C.O.O. & Vice President - Director.        Chairman & Chief Executive
                                                 Officer

Date: 30th Aug. 2000                         Date: 30th Aug. 2000

                                       39
<PAGE>

                          ATTACHMENTS A-1 THROUGH A-3

           BNP7787 Products, Karenitecin Products & Mercedes Products

                          ATTACHMENTS A-4 THROUGH A-5

          PDE4 Products and COX-2 Products - To Be Provided by Grelan

                                 ATTACHMENT B-1

            BioNumerik Patent Rights - To Be Provided by BioNumerik

                                 ATTACHMENT B-2

                Grelan Patent Rights - To Be Provided by Grelan

                                  ATTACHMENT C

                  Venture Product Scenarios and Illustrations

                                  ATTACHMENT D

       Target Development & Commercialization Plan Milestones for BNP7787

                                  ATTACHMENT E

                                 Patent Matters

                                  ATTACHMENT F

                    BioNumerik Audited Financial Statements

                                  ATTACHMENT G

                      Grelan Audited Financial Statements

                                       40
<PAGE>
                                 ATTACHMENT A-1

         "BNP7787 Products" means the compound identified as BNP7787, DISODIUM
2,2' -DITHIOBISETHANE SULFONATE (dimesna), all pharmaceutical salts and
prodrugs thereof, and all pharmaceutical formulations of BNP7787.

                                       41
<PAGE>
                                 ATTACHMENT A-2

         "Karenitecin Products" means the compound identified as BNP1350, IUPAC
name 4-ETHYL-4-HYDROXY-11-TRIMETHYLSILYLETHYL-(S)-1H-PYRANO [3' :4' :6 :7]
INDOLIZINO [1,2-b]QUINOLINE-3,14(4H, 12H)-DIONE, (also referred to as
7-(2'-TRIMETHYLSILYLETHYL) CAMPTOTHECIN), all pharmaceutical salts and prodrugs
thereof, and all pharmaceutical formulations of BNP1350.

                                       42
<PAGE>
                                 ATTACHMENT A-3

         "Mercedes Products" means those pharmaceutical formulations that
include paclitaxel (and other taxane derivatives as that term is defined in the
art) and N-Methyl pyrrolidone (NMP).

                                       43
<PAGE>
                                 ATTACHMENT A-4

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       44
<PAGE>
                                 ATTACHMENT A-5

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       45
<PAGE>

                                 ATTACHMENT B-1

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       46
<PAGE>

                                 ATTACHMENT B-2

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       47
<PAGE>
                                  ATTACHMENT C

Set forth below are some examples of what are reasonable expected ranges for the
pricing and sales prices for drugs in Japan - these ranges can vary from the
examples given below:

1. [**] dose of drug is [**] the retail price to patient and government
reimbursement.

2. Hospital or Pharmacy Purchase Price usually is about [**] respectively, [**].
The hospital or pharmacy will typically purchase a drug from a wholesaler or
distributor, not directly from a manufacturer or pharmaceutical company.

3. Distributor or Wholesaler Price usually is about [**] of [**] - if the
Venture or a third party owned by or affiliated with the Venture directly
distributes and sells the drug, then the profit margin (above the Manufacturing
Price and royalty) will be [**] between BioNumerik and GRELAN. The same would
apply in the event that the Venture or a third party owned by or affiliated with
the Venture directly distributes and sells the drug to a Hospital or Pharmacy.

4. Royalty is usually about [**] - this is [**] between BioNumerik and Grelan
(e.g.: [**] paid to BioNumerik and [**] paid to Grelan).

5. Manufacturing Price for a contract manufacturer is estimated at about [**] -
this is paid to the party that has manufacturing rights to the product and
represents the price to manufacture the bulk drug [**] including fill and
finish, label, store, record (adds another [**]  and the margin of expected
Manufacturer's profit (approximately [**] to the manufacturer.

     Some scenarios for illustration of the foregoing:

     a.   The Venture drug sold is by third party distributor that has licensed
          the right to distribute, market and sell the drug in Japan. The [**]
          for the approved drug is [**] per unit. Grelan and BioNumerik would
          each receive [**] royalty payment [**] per unit) by the Japanese
          distributor. The total royalty that BioNumerik would receive from this
          would be [**] per unit.

     b.   In the above scenario, the Manufacturing Price for the Venture product
          is [**] (estimated at [**] BioNumerik would sell the drug directly to
          the third party distributor based on a [**] Manufacturing Price to be
          paid by the third party Japanese distributor. In this scenario,
          BioNumerik would also receive a manufacturing margin payment from the
          distributor of approximately [**]. In this scenario this would amount
          to approximately an additional [**] per unit. BioNumerik could also
          optionally sell the product directly to the Venture; in this scenario
          the manufacturer's profit margin would still be [**] and paid by the
          Venture to BioNumerik.

     c.   The Venture drug sold by Venture or a Venture-owned third party to
          distributor, wholesaler or hospital/pharmacy. The [**] for the
          approved drug is [**] per unit. The Manufacturing Price is [**] (based
          on [**]) and the price range that the drug is sold to distributor,
          wholesaler or hospital/pharmacy ranges from [**] The specific points
          of sale of drug units will be accounted for and payments will be made
          accordingly, with adjustment and reimbursement for any over- payment
          or under-payment to Grelan or BioNumerik for any units actually sold.
          Any profit margin resulting from the direct distribution or sale of
          the Venture product by the Venture or its affiliates would be paid to
          the Venture taking into account the Manufacturing Price (which is
          estimated to range from [**] this profit margin (meaning above that of
          any royalty and/or Manufacturing Price) would be [**] and paid to
          BioNumerik and Grelan from the Venture. BioNumerik shall also be paid
          a manufacturer's profit margin of approximately [**] for each unit. If
          there is any royalty payment, then this will be [**] between
          BioNumerik and Grelan as well. In this example, BioNumerik would sell
          the product to the Venture for [**] (Manufacturing Price of [**] plus
          Manufacturing Profit Margin of [**] plus [**] (the
          Wholesale/Distribution and Hospital or Pharmacy Price) per unit for a
          total of [**] per unit. The Venture would sell the unit to the
          distributor, wholesaler or hospital or pharmacy for [**] per unit and
          Grelan and BioNumerik would each be paid from the Venture a total
          amount of [**] per unit. If there is a royalty payment, then it shall
          be [**] between Grelan and BioNumerik and shall be part of the
          BioNumerik sales price of the product to the Venture.

     [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
     SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
     REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

     [**] BioNumerik and Grelan will have certain rights to determine and
     establish prices for the Venture Products. The Manufacturing price for
     Venture Products BN will be established by BioNumerik and will include the
     costs for all raw materials and manufacturing along with the margin of
     profit for the manufacturer - this will be negotiated at the time of any
     third party license or will be established by mutual agreement in the event
     the Venture or an affiliate distributes and sells the products directly.
     The product royalty percentage will be established by BioNumerik and Grelan
     based on the license agreement with the third party distributor (e.g., a
     large pharmaceutical company) royalty obligations to the Venture. In the
     event the Venture or an affiliate decides to directly distribute or sell
     Venture products to a Japanese wholesaler/distributor, hospital or pharmacy
     the corresponding sales prices for each endpoint of sale will be jointly
     agreed upon by BioNumerik and Grelan for all Venture products in the
     territory of Japan. BioNumerik will have the sole right and authority to
     establish prices in all territories excluding Japan for all Venture
     Products BN, the rights to which are licensed to the Venture.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       48
<PAGE>

                                  ATTACHMENT D
                                   (2 Pages)

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       49
<PAGE>

                                  ATTACHMENT E
                                   (2 Pages)

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       50
<PAGE>

                                  ATTACHMENT F
                                   (22 Pages)

Bionumerik Pharmaceuticals, Inc.

Financial Statements

Years Ended March 31, 2000, 1999, and 1998 with Report of Independent Auditors

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       51
<PAGE>

                                  ATTACHMENT G
                                   (6 Pages)

                              FINANCIAL STATEMENTS

                        Year Ended 30th September, 1999

                        GRELAN PHARMACEUTICAL CO., LTD.

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       52<PAGE>
                                                                    EXHIBIT 10.5

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                                  AGREEMENT FOR

                       MANUFACTURING AND SUPPLY OF BNP7787

                Made as of April 12, 2001 (the "Effective Date")

                                 by and between

                        BIONUMERIK PHARMACEUTICALS, INC.,
                   (hereinafter referred to as "BioNumerik"),
                    a corporation duly organized and validly
                     existing under the laws of the State of
                    Texas with its principal offices at Suite
                           1250, 8122 Datapoint Drive,
                           SAN ANTONIO, TX 78229, USA

                                       and

                         SUMIKA FINE CHEMICALS CO., LTD.
                     (hereinafter referred to as "Sumika"),
   a corporation duly organized and validly existing under the laws of Japan,
     with its principal offices at 1-21, Utajima 3-chome, Nishiyodogawa-ku,
                              Osaka 555-0021, Japan

1                 DEFINITIONS

                  Unless otherwise expressly set forth herein, the following
                  terms shall have the meanings set forth below:

1.1               Calendar Quarter
                  Shall mean each three (3) month period ending on March 31,
                  June 30, September 30 or December 31.

1.2               Compound

                  Shall mean the compound 2,2'-Dithio-Bis-Ethane sulfonate,
                  disodium salt, also known as BNP7787.

1.3               Confidential Information
                  Shall mean all information, whether technical or
                  non-technical, trade secrets, discoveries, data, drawings,
                  techniques, documents, models, samples and know-how, whether
                  or not patented or patentable, owned or possessed by the
                  Parties on the date of this Agreement or later developed by
                  them.

1.4               Party
                  Shall mean BioNumerik or Sumika, and when used in the plural
                  form both BioNumerik and Sumika.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

                                        1

<PAGE>

1.5               Product(s) or Finished Dosage Form
                  Shall mean any pharmaceutical composition containing the
                  Compound as the pharmacologically active ingredient.

1.6               Specifications
                  Shall mean the mutually agreed upon specifications for the
                  Compound attached on Annex 1 hereto.

2                 MANUFACTURE AND SUPPLY OF COMPOUND

2.1               Subject to the provisions of this Agreement, BioNumerik shall
                  purchase from Sumika and Sumika shall supply, at the price set
                  forth in Annex 2 attached hereto, a minimum of [**] of
                  BioNumerik's annual actual requirements of the Compound until
                  the cumulative total amount of the Compound purchased by
                  BioNumerik from Sumika reaches 300 metric tons (MT).
                  BioNumerik may also consider additional procurements of its
                  Compound from other manufacturers in accordance with Section
                  2.3.

2.2               The Compound shall be manufactured and delivered in accordance
                  with the Compound Specifications indicated in Annex 1, which
                  will be mutually updated from time to time by the Parties. In
                  addition, manufacturing of the Compound by Sumika will be
                  conducted in compliance with current U.S. FDA Good
                  Manufacturing Practices (cGMP), ISO9002 and International
                  Conference on Harmonization (ICH) regulations and guidelines.
                  BioNumerik shall not export the Compound sold by Sumika
                  hereunder or the Product(s) produced from such Compound to any
                  country or territory where such export would be in violation
                  of the patent laws of such territory. Prior to any export of
                  Compound(s) or Product(s), BioNumerik and Sumika shall, if
                  requested by either party, discuss in good faith the matter of
                  whether such export would violate the patent laws of the
                  intended country or territory of export. In addition to the
                  foregoing, BioNumerik shall have no obligation to purchase
                  from Sumika any percentage of its requirements of Compound
                  with respect to a territory to which it is unable to export
                  Compound as provided in the Section 2.2 or to which Sumika
                  does not agree to export Compound as provided in Section 2.9.
                  Sumika will not sell the Compound to any party other than
                  BioNumerik without BioNumerik's prior written consent.

                  Sumika shall be entitled to appoint any trading company it
                  deems appropriate to act as an intermediary between the
                  Parties for the purchase, sale and delivery of the Compound,
                  provided that the costs paid or payable by BioNumerik shall
                  not increase because of such appointment and such trading
                  company shall be reasonably acceptable to BioNumerik.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                        2

<PAGE>

2.3               In the event BioNumerik considers procurements of its Compound
                  in addition to the amount (a minimum of [**] of BioNumerik's
                  annual actual requirements of the Compound until the
                  cumulative total amount of the Compound purchased by
                  BioNumerik from Sumika reaches 300 MT) to be purchased
                  pursuant to Section 2.1, BioNumerik may conduct such
                  additional procurements from other manufacturers, provided
                  BioNumerik shall give Sumika notice of such consideration
                  prior to any farther contracting with another supplier or
                  suppliers for such additional Compound amounts. In such
                  circumstances, Sumika may, a its option, provide BioNumerik
                  with a bid containing new price, delivery amount and other
                  material terms under which it would manufacture and transport
                  Compound on a non-exclusive basis to BioNumerik. It is the
                  hope of the Parties that Sumika will manufacture A significant
                  and major portion of the Compound to be supplied to
                  BioNumerik, subject to meeting the competitive requirements of
                  price, quality, supply, delivery and other material terms
                  relative to other potential or active manufacturers. If such
                  bid from Sumika is on substantially competitive terms with
                  BioNumerik's other alternatives for manufacturing Compound,
                  then BioNumerik and Sumika will negotiate in good faith to
                  enter into an amendment to this Agreement providing for the
                  manufacture by Sumika of a significant portion of the Compound
                  amounts required by BioNumerik, which portion will be
                  determined by BioNumerik in its discretion based on
                  BioNumerik's evaluation of considerations including the need
                  to manage risk by having more than one manufacturer of
                  Compound. In the event of any unsuccessful bid by Sumika,
                  BioNumerik will describe to Sumika the categories in which its
                  bid was deemed not competitive. In the absence of any bid from
                  Sumika (within 60 days of receipt of the notice from
                  BioNumerik) to manufacture Compound on substantially
                  competitive terms to BioNumerik's other bid, BioNumerik shall
                  be free to utilize such other alternatives for the manufacture
                  of manufacturing alternatives Compound. Until an amendment to
                  this Agreement is entered into by the Parties, Sumika's
                  obligations shall continue to manufacture and supply Compound
                  as provided in this Agreement. The Parties recognize that
                  Sumika shall have reasonable opportunities to be a significant
                  manufacturer of Compound as provided above, but that no
                  assurance can be given that Sumika will be a sole source for
                  the Compound due to the expected volume of use,
                  taxation/importation costs that may be encountered in various
                  territories, and other considerations.

2.4               BioNumerik and Sumika will regularly communicate concerning
                  the purchase and sale of the Compound. BioNumerik shall
                  provide to Sumika, no later than the 15th day following the
                  end of each Calendar Quarter, a forecast of its estimated
                  purchase orders from Sumika for the 12 calendar months
                  following the month in which the forecast is transmitted.
                  BioNumerik may make more frequent forecasts as it may deem
                  necessary. Except as otherwise provided herein, the terms and
                  conditions of all sales of the Compound by Sumika to
                  BioNumerik shall be in accordance with an acknowledgement
                  ("Acknowledgement") provided by Sumika to BioNumerik in
                  response to each purchase order placed by BioNumerik
                  hereunder. The quantity of each shipment of the Compound
                  specified in each Acknowledgement shall be definitive for all
                  purposes herein absent conclusive error. BioNumerik shall
                  provide Sumika with purchase order(s) for Compound at least
                  [**] prior to the time BioNumerik requires such Compound.
                  Each minimum purchase order amount of the Compound by
                  BioNumerik shall be [**]. During the term of this Agreement,
                  Sumika shall provide BioNumerik with such quantities of
                  Compound as may be requested by BioNumerik and accepted by
                  Sumika in accordance with the terms of this Agreement.

2.5               BioNumerik shall test and approve the quality of delivered
                  Compound within 21 days after receipt of the Compound. If
                  BioNumerik fails to so test or approve, BioNumerik shall be
                  deemed to have tested and approved the quality of such
                  Compound. If BioNumerik informs Sumika within the said 21
                  days' period that the delivered Compound does not meet the
                  Specifications, BioNumerik shall, within 10 days thereafter,
                  send back the non-conforming Compound, and disclose the test
                  results concerning such Compound, to Sumika. Then, the Parties
                  shall cooperate with each other in promptly examining such
                  test results and promptly comparing the non-conforming
                  Compound in question and the sample of the Compound retained
                  by Sumika. If the Compound proves to be non-conforming at the
                  time of delivery to BioNumerik, upon BioNumerik's written
                  request, Sumika will promptly send to BioNumerik without
                  additional charge replacement amounts of the ordered Compound
                  that were non-conforming, and provide BioNumerik with a credit
                  equal to the transportation costs of such non-conforming
                  Compound. Sumika's foregoing obligations shall be the sole
                  remedy to BioNumerik Sumika's total responsibility shall not

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

                  exceed the value of the Compound in question plus related
                  shipping costs. Prior to approval of the Compound for
                  commercial sale, BioNumerik shall warehouse any back-up supply
                  of Compound purchased by BioNumerik from Sumika. If the
                  Parties discuss and agree that Sumika will hold such inventory
                  on behalf of BioNumerik, then Sumika shall send BioNumerik lot
                  sample(s) of the Compound and then BioNumerik shall test and
                  approve the quality of such sample(s) within 21 days of
                  receipt thereof and shall thereafter make the payment for such
                  Compound within 30 days; provided, however, that if the
                  quality of the Compound has been approved in advance by
                  BioNumerik, then BioNumerik shall make the payment within 30
                  days after BioNumerik's order therefor with Sumika. Such
                  Compound shall be subject to the product warranties set forth
                  in Article 4 of this Agreement.

2.6               The price of the Compound shall be on a [**] and in accordance
                  with Annex 2 attached hereto. In the event that BioNumerik
                  requests for the delivery of the Compound on other trade
                  terms, any increase of transportation and other costs incurred
                  by such request shall be borne by BioNumerik. Payment for all
                  Compound purchased from Sumika by BioNumerik in accordance
                  with this Agreement and approved by BioNumerik in accordance
                  with Section 2.5 shall be made in full within 30 days after
                  Compound satisfying the required Specifications are received.
                  BioNumerik shall make such payment without set-off,
                  counterclaim, or other such rights which BioNumerik may claim
                  against Sumika. Overdue payments shall accumulate interest
                  thereon at the rate of 14 percent per annum. Payment by
                  BioNumerik hereunder shall be made by wire transfer in
                  accordance with Annex 3.

2.7               As a part of this Agreement, Sumika shall maintain all of the
                  appropriate Specifications and standard operating procedures
                  related to the manufacturing of the Compound. These will be
                  treated as controlled documents and will be maintained
                  utilizing a suitable document control procedure to ensure
                  proper issuance and change, respectively. During the term of
                  this Agreement and for a period of at least two years
                  thereafter, Sumika shall maintain records of inspection and
                  testing, lab notebooks and procedures made in connection with
                  the manufacturing work conducted under this Agreement. In
                  addition, as a part of this Agreement Sumika shall prepare and
                  maintain an updated Drug Master FIle (DMF) for the Compound
                  for the United States, the European Union, and Japan and shall
                  answer any deficiency letter that the U.S. FDA and/or other
                  relevant regulatory health authority may issue to BioNumerik
                  regarding the manufacturing process for the Compound, provided
                  that the Parties shall discuss and agree in writing upon the
                  costs and expenses required for the preparation of such DMF.
                  The costs to prepare a DMF are estimated to consist of
                  approximately [**] for document compilation of analytical
                  matters; [**] for document compilation of CMC matters; and
                  [**] for finishing the DMF compilation and preparation; and in
                  any event the total DMF cost shall not exceed [**].

[**] Certain INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

                                        3
<PAGE>

2.8               Sumika shall keep BioNumerik regularly informed of the status
                  and progress of the manufacturing of Compound through regular
                  telephone or e-mail updates and through written summaries
                  provided to BioNumerik on a quarterly basis. Sumika recognizes
                  and agrees that any change in the process for preparation or
                  manufacture of the Compound (whether planned or unplanned)
                  must be approved in advance in writing by BioNumerik.

2.9               Subject to the limitations on exports contained in Section 2.2
                  hereof, Sumika shall be responsible for complying with all
                  transport regulations and export laws applicable under the
                  laws of Japan and any export territory agreed upon by the
                  Parties concerning the provision of the Compound to BioNumerik
                  in accordance with this Agreement. BioNumerik shall be
                  responsible for complying with all transport regulations and
                  export laws applicable under the federal, state and local laws
                  of the United States of America and other territories
                  designated by the Parties concerning the Compound. Sumika will
                  use reasonable best efforts to assure that the Compound will
                  be transported to BioNumerik in a reasonable and appropriate
                  manner, which will include reasonable consideration of
                  environmental conditions of the shipping, cGMP requirements,
                  and the procedures and precautions to be followed by the
                  shipper.

3                 INSPECTIONS AND CONTROLS

3.1               Subject to confidentiality obligations contained in Section 7,
                  Sumika agrees to allow inspections of its manufacturing
                  facilities in which the Compound is being manufactured,
                  analyzed or tested, by representatives of BioNumerik or Grelan
                  Pharmaceutical Co., Ltd. ("Grelan"), as well as FDA and other
                  material regulatory authorities of the U.S. or other
                  governments, during normal working hours upon prior written
                  notice to Sumika. Sumika shall grant access to such premises
                  and to the documentation necessary for or appropriate to the
                  manufacturing and quality control of the Compound. BioNumerik
                  shall cause Grelan to comply with the Confidentiality
                  obligations set forth in this Agreement and shall be
                  responsible for any breach of such obligations by Grelan.

3.2               Sumika shall ensure all manufacturing, test and inspection
                  equipment is maintained under a documented calibration program
                  that is ISO9002 and ICH compliant. This includes providing
                  equipment calibration certifications as required.

3.3               Sumika will maintain environmental controls, including
                  particulate and bioburden monitoring, pest controls and
                  housekeeping procedures in accordance with FDA cGMP, ISO9002
                  and ICH regulations and guidelines. The use of supplies of
                  process water, air and particulate handling, etc., for cGMP
                  manufacture of the Compound, shall be consistent with FDA cGMP
                  specifications and ICH regulations and guidelines.

3.4               Sumika shall maintain a Quality Control department, which is a
                  distinct department separate from manufacturing. Sumika
                  Quality Control/Quality Assurance will perform incoming,
                  in-process and finished product inspections, review records,
                  perform line clearances, maintain batch history records,
                  provide batch history records for review and accuracy and
                  completeness and provide product release services in
                  accordance with cGMP and ICH regulations and guidelines.

                                        4

<PAGE>

3.5               Sumika will promptly notify BioNumerik of any FDA or other
                  material regulatory inspection of Sumika related to the
                  Compound, and will promptly provide BioNumerik with a copy of
                  documentation and Sumika's correspondence and plans to address
                  any deficiencies relating to such inspection.

4                 PRODUCT WARRANTIES

4.1               Sumika warrants and represents exclusively to BioNumerik that
                  the Compound manufactured by Sumika and delivered to
                  BioNumerik hereunder shall, at the time of shipment, conform
                  to the Specifications and be manufactured in accordance with
                  all applicable laws and regulations relating to the
                  manufacture of the Compound, including but not limited to,
                  applicable supranational, national and local laws in the
                  country when and where manufacture occurs, current U. S. FDA
                  Good Manufacturing Practices (cGMP), ISO9002 and ICH
                  regulations and guidelines. Sumika further represents that the
                  API is still in a development process and that the shelf life
                  stability of API will be determined based on additional
                  stability testing data that is obtained in the future. EXCEPT
                  AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SUMIKA MAKES NO
                  REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED,
                  INCLUDING BUT NOT LIMITED TO, ANY WARRANTY OF MERCHANTABILITY
                  OR FITNESS FOR ANY INTENDED USE OR PURPOSE. Notwithstanding
                  the foregoing, BioNumerik shall have no obligation to purchase
                  any Compound that does not meet the Specifications as provided
                  in Section 2.5 hereof.

5                 DEBARMENT CERTIFICATION

5.1               Sumika warrants that it will not knowingly use in connection
                  with the services rendered under this Agreement in any
                  capacity the services of any person debarred under the U.S.
                  Food, Drug & Cosmetic Act or any other similar law or
                  regulation governing drug manufacturing.

6                 INDEPENDENT CONTRACTOR STATUS

6.1               Each of the Parties in performing this Agreement shall be and
                  be deemed to be acting as an independent contractor and not as
                  the agent or employee of the other. Accordingly, BioNumerik
                  shall purchase the Compound from Sumika, which Sumika has
                  manufactured in accordance with the Specifications. BioNumerik
                  and/or its designated affiliates or agents shall then
                  manufacture the Finished Dosage Form in accordance with
                  BioNumerik's specification therefor. Neither Sumika nor
                  BioNumerik shall have any authority whatsoever to act as agent
                  or representative of the other Party nor any authority or
                  power to contract or create any obligation or liability on
                  behalf of the other Party or otherwise bind any other Party in
                  any way for any purpose.

                                        5

<PAGE>

7                 CONFIDENTIALITY

7.1               Each Party shall hold all Confidential Information received
                  from the other Party in strictest confidence and shall use the
                  same level of care to prevent any unauthorized use or
                  disclosure of such Confidential Information as it exercises in
                  protecting its own information of similar nature. The Parties
                  shall not disclose any Confidential Information received from
                  the other Party to any third party without the prior written
                  consent of the other Party.

7.2               The Confidential Information shall be supplied to the Parties
                  in written form and shall be identified as being confidential
                  and disclosed under the provisions of this Agreement. Any
                  information that is disclosed in oral form shall be confirmed
                  in writing within sixty (60) days after disclosure and be
                  deemed included as Confidential Information within the scope
                  of this Agreement.

7.3               Each Party shall have the right to disclose the Confidential
                  Information of the other Party to the minimum number of those
                  officers and employees who need to know it for the purposes of
                  this Agreement. Such disclosure is allowed only on condition
                  that the persons to whom the Confidential Information will be
                  disclosed shall be, by law, contract or other undertaking,
                  under confidentiality obligations corresponding to those set
                  out in this Agreement.

7.4               The disclosing Party retains all rights to its Confidential
                  Information.

7.5               The confidentiality obligations of this Agreement shall not
                  apply to:

                  a)       Confidential Information which at the time of the
                           disclosure is in the public domain; or

                  b)       Confidential Information which, after disclosure,
                           becomes part of the public domain otherwise than by
                           breach of this Agreement; or

                  c)       Confidential Information which can be established by
                           reasonable and competent proof to have already been
                           in the receiving Party's possession prior to
                           disclosure and was not acquired, directly or
                           indirectly, from the disclosing Party; or

                  d)       Confidential Information which a receiving Party
                           shall receive from a third party who has the legal
                           right to disclose it and who would by disclosure not
                           breach, directly or indirectly, any confidentiality
                           obligation to either Party; or

                  e)       Confidential Information which is released for
                           disclosure by prior written consent of the disclosing
                           Party; or

                  f)       Confidential Information which has been independently
                           developed by a Party hereto without the use or
                           benefit of Confidential Information received from the
                           other Party; or Confidential Information which is
                           required to be disclosed by law or by order of court
                           of competent jurisdiction, provided that due advance
                           notice is given to the other Party of such a
                           requirement and also such disclosure is then made
                           only to the minimum extent so required.

                                        6

<PAGE>

7.6               The burden of proving that any of the above exceptions is
                  applicable to a Party to relieve it of its liability or
                  obligations hereunder shall be upon the Party claiming such
                  exception(s).

7.7               Grelan shall comply with the confidentiality obligations set
                  forth herein as if Grelan is a party to this Agreement.

8                 INTELLECTUAL PROPERTY RIGHTS

8.1               a)       As used herein "Intellectual Work Product" means all
                           inventions, modifications, discoveries, improvements,
                           processes, techniques, documentation, scientific and
                           technical data, drawings and other information other
                           than the Sumika Technology, that is generated as a
                           result of the manufacturing services performed for
                           BioNumerik by Sumika in accordance with this
                           Agreement. "Sumika Technology" means all present and
                           future documentation, scientific and technical data,
                           processes, test procedures, information, know-how,
                           techniques, technology, patents, patent rights,
                           copyrights, trade secret rights, inventions,
                           intellectual property rights, and other information
                           and techniques that are owned, developed or licensed
                           by Sumika (other than those developed hereunder or in
                           connection with the manufacturing or other projects
                           performed for BioNumerik by Sumika). BioNumerik shall
                           not own any of the Sumika Technology. However, Sumika
                           shall use the Sumika Technology, as far as it is
                           applicable, in order to efficiently carry out the
                           manufacture of the Compound.

                  b)       The Parties hereto understand and agree that no
                           rights are being conveyed to Sumika (or any of their
                           affiliates) to use any BioNumerik Technology (as
                           hereafter defined) for any purpose other than the
                           sole purpose of preparing the Compound for the
                           benefit of BioNumerik in accordance with the terms of
                           this Agreement. As used herein, "BioNumerik
                           Technology" means all present and future
                           documentation, scientific and technical data,
                           processes, test procedures, information, know-how,
                           techniques, technology, patents, patent rights,
                           copyrights, trade secret rights, inventions,
                           intellectual property rights, and other information
                           and techniques that are owned, developed, or licensed
                           by BioNumerik. Prior to and during the course of
                           developing this Agreement, and in the future during
                           the course of this Agreement, BioNumerik has provided
                           and may provide Sumika with confidential and
                           proprietary enabling disclosures pertaining to the
                           composition, processes and conditions for
                           manufacturing, potential uses and other commercially
                           sensitive information relating to the Compound.

                                        7

<PAGE>

8.2               a)       Sumika acknowledges that BioNumerik is the sole and
                           exclusive owner of all Intellectual Work Product
                           (except the Sumika Technology, as described above in
                           8.1). In consideration of the covenants contained
                           herein, and for other good and valuable consideration
                           set forth herewith, Sumika hereby assigns and
                           transfers to BioNumerik and its successors and
                           assigns all right, title and interest that Sumika has
                           or may later acquire in and to the Intellectual Work
                           Product under copyright, patent, trade secret and
                           trademark law. Such assignment includes the
                           assignment of the entire right, title and interest in
                           and to all applications for letters patent and any
                           and all letters patent or patents in the United
                           States of America and all foreign countries which may
                           be granted on and in connection with the Intellectual
                           Work Product.

                  b)       Sumika agrees to co-operate with BioNumerik so that
                           BioNumerik may enjoy to the fullest extent the entire
                           right, title and interest in and to the Intellectual
                           Work Product. In connection therewith, Sumika agrees
                           to execute, if necessary, additional papers and
                           documents and to take all actions requested by
                           BioNumerik in order to (a) further evidence ownership
                           of the Intellectual Work Product by BioNumerik and
                           its successors and assigns and (b) allow BioNumerik
                           to procure, maintain and enforce all letters patent
                           and intellectual property rights to the Intellectual
                           Work Product. BioNumerik agrees to reimburse Sumika
                           all reasonable costs in relation to the production of
                           additional papers and documents as well as all
                           actions requested by BioNumerik pursuant to this
                           Section 8.2(b).

                  c)       In addition, in the event the manufacturing efforts
                           hereunder result in a synthesis or manufacturing
                           process for the Compound that incorporates Sumika
                           Technology, BioNumerik shall be granted, and is
                           hereby granted, a worldwide, personal, non-exclusive,
                           perpetual, royalty-free, non-sublicensable license to
                           practice said inventions and technology to the extent
                           they relate to such synthesis and manufacturing (so
                           long as such grant is not in violation of Sumika's
                           agreements with other parties existing as of the date
                           of this Agreement). BioNumerik will not transfer the
                           Sumika Technology to any third party without the
                           prior written agreement of Sumika, and no third party
                           may use the Sumika Technology without the prior
                           written agreement of Sumika.

d)                         [**].

8.3               Except for use for the purposes as defined in this Agreement,
                  no right, title, interest, or license in or to any trademark,
                  patent, copyright or service mark or symbol or any other
                  intellectual property right of a Party is granted to the other
                  Party under this Agreement.

9                 INDEMNIFICATION PROVISIONS

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

                                        8

<PAGE>

                  a.       Sumika shall not be responsible for any product
                           liability relating to or arising from any Compound
                           supplied by Sumika under this Agreement and the
                           Product(s) produced from such Compound so long as the
                           Compound and the production method of such Compound
                           have been approved by BioNumerik, unless such
                           approval is based on inappropriate data provided by
                           Sumika.

9.1               BioNumerik will indemnify and hold harmless Sumika, its
                  affiliates, any present or future parent or subsidiary of
                  them, and their respective officers, directors, employees,
                  counsel, agents and affiliates (the "Indemnified Sumika
                  Parties") against any and all losses, liabilities, damages,
                  costs and expenses including, but not limited to, reasonable
                  attorney fees and any and all reasonable expenses incurred in
                  defending against any litigation, commenced or threatened, or
                  any claim, and any and all amounts reasonably paid in
                  settlement of any claim or litigation commenced or threatened
                  ("Losses"), arising out of (i) product liability, patent and
                  trademark infringement or other suits and claims relating to
                  rights under BioNumerik's control and regarding any active
                  pharmaceutical ingredient or raw materials, including but not
                  limited to, any bulk drug, or the Compound, Products or
                  Finished Dosage Form, including but not limited to the
                  sterilization, bottling or production processes thereof, (ii)
                  any failure by BioNumerik to comply with any applicable
                  governmental regulation (including, without limitation, any
                  applicable environmental laws), (iii) any breach of any
                  representation, warranty, covenant or agreement of BioNumerik
                  contained in this Agreement, (iv) the use by Sumika of any raw
                  or component material(s) supplied by BioNumerik to Sumika or
                  by a third party on BioNumerik's behalf, or (v) the promotion,
                  marketing, distribution and sale, whether directly or through
                  distributors, of the Compound; PROVIDED, HOWEVER, THAT
                  BIONUMERIK SHALL NOT INDEMNIFY OR HOLD HARMLESS ANY OF THE
                  INDEMNIFIED SUMIKA PARTIES TO THE EXTENT THAT SUMIKA OR ANY
                  INDEMNIFIED SUMIKA PARTIES ARE RESPONSBILE BY NEGLIGENCE OR
                  WILLFUL ACT FOR SUCH LOSSES, LIABILITIES, DAMAGES, COSTS AND
                  EXPENSES.

9.2               Sumika will indemnify and hold harmless BioNumerik, its
                  affiliates, any present or future parent or subsidiary of any
                  of them, and their respective officers, directors, employees,
                  counsel, agents and affiliates (the "Indemnified BioNumerik
                  Parties") against any and all Losses arising out of (i) any
                  breach of any representation, warranty, covenant or agreement
                  of Sumika contained in this Agreement, or (ii) any failure by
                  Sumika to comply with any applicable governmental regulation
                  (including, without limitation, any applicable environmental
                  laws), BUT ONLY TO THE EXTENT SUCH FAILURE REFERRED TO WITHIN
                  (ii) OF THIS PARAGRAPH IS ATTRIBUTABLE TO SUMIKA'S BREACH OF
                  THIS AGREEMENT, OR SUMIKA'S FAILURE TO MANUFACTURE ANY PRODUCT
                  IN CONFORMANCE WITH THE SPECIFICATIONS; provided further that
                  Sumika will not indemnify and hold harmless Indemnified
                  BioNumerik Parties for any losses arising out of BioNumerik's
                  negligence or willful act.

9.3               Conditions of Indemnification: With respect to any
                  indemnification obligations of either Party to the other Party
                  under this Agreement, the following conditions must be met for
                  such indemnification obligations to become applicable:

                                        9

<PAGE>

                  a)       The indemnified Party shall notify the indemnifying
                           Party promptly in writing of any claim which may give
                           rise to an obligation on the part of the indemnifying
                           Party hereunder;

                  b)       The indemnifying Party shall be allowed to timely
                           undertake the sole control of the defense of any such
                           action and claim, including all negotiations for the
                           settlement, or compromise of such claim or action at
                           its sole expense;

                  c)       The indemnified Party shall at its sole expense
                           render reasonable assistance, information,
                           co-operation and authority to permit the indemnifying
                           Party to defend such action.

9.5               BioNumerik shall notify Sumika in writing of any defect that
                  it learns of, which is likely to affect the manufacture of the
                  Compound as contemplated by this Agreement.

10                TERM AND TERMINATION

10.1              This Agreement shall enter into force as of the Effective Date
                  of the Agreement and unless earlier terminated, shall continue
                  in full force and effect until BioNumerik's fulfilling and
                  completing its obligations set forth in Section 2.1 unless
                  extended by agreement of the Parties. Sections 4, 7, 8, 9, 11,
                  16 and 17 shall survive any termination of this Agreement.

10.2              The Parties may terminate this Agreement upon mutual written
                  agreement at any time during the Term of this Agreement.

10.3              Either party may terminate this Agreement without penalty at
                  any time without payment of any compensation by giving six
                  months prior written notice of termination to the other party,
                  if either party believes that such termination is reasonably
                  justified, provided that, if requested by the non-terminating
                  party, the terminating party shall discuss such termination
                  with the other party for a period of up to 60 days in a good
                  faith and best effort to find a mutually agreeable solution
                  for avoiding such termination. If the circumstances require
                  more than 60 days to adequately discuss such matter, the 60
                  days discussion period set forth in the preceding sentence
                  will be extended to up to 180 days (inclusive of the 60 day
                  discussion period described above) at the request of either
                  party. In the event that both parties fail to find a mutually
                  agreeable solution for avoiding such termination in such a
                  period of 60 days or 180 days as stipulated above, this
                  Agreement shall be terminated, provided however that ,
                  notwithstanding the provisions of Section 10.1, (i) any rights
                  and obligations of each party under this Agreement except
                  those stipulated in clauses (ii) and (iii) of this sentence
                  set forth below shall lose effect on the date of such
                  termination, (ii) the Parties shall be responsible for
                  fulfilling and completing all orders for Compound made by
                  BioNumerik prior to the date of such termination, and (iii)
                  Sections 4, 7, 8, 9, 11, 16, and 17 shall survive any such
                  termination.

                                       10

<PAGE>

                  Either Party shall have the right, without prejudice to any
                  other rights or remedies available to it, to terminate this
                  Agreement for cause with immediate effect by written notice to
                  the other Party in any of the following events:

                  a)       The other Party defaults in the performance of any of
                           its obligations under this Agreement and such default
                           continues unremedied for thirty (30) days from notice
                           to the defaulting Party;

                  b)       The other Party intentionally makes (or is discovered
                           to have intentionally made) any material false
                           representations or omissions, reports or claims in
                           connection with the business relationships of the
                           Parties;

                  c)       Any of the representatives of the Parties engages in
                           (or is discovered to have engaged in) fraudulent,
                           criminal or negligent conduct in connection with the
                           business relationships of the Parties;

                  d)       The other Party files a petition in bankruptcy, is
                           adjudicated bankrupt, files for reorganization, is
                           placed in liquidation, makes a general assignment for
                           the benefit of its creditors, becomes insolvent or is
                           otherwise unable to fulfill its business obligations;

                  e)       Any change occurs with respect to the ownership of
                           the other Party by virtue of dissolution,
                           reorganization or transfer or sale of fifty percent
                           (50 %) or more of the outstanding stocks of the other
                           Party to a third party having activities within the
                           pharmaceutical field.

11                LIMITATION OF DAMAGES

11.1              In no event shall either Party be liable to the other Party or
                  third parties for any indirect, incidental or consequential
                  damages, such as e.g. lost profits in connection with its
                  performance under this Agreement or any breach thereof. The
                  restrictions of liability to compensate damages stipulated for
                  in this article shall not be applied to any breach of the
                  intellectual property rights of Sumika or BioNumerik or its
                  principals, including but not limited to rights of patent,
                  copyright and trademark or unauthorized disclosure of the
                  trade secrets or other confidential information of the same
                  provided to either of the Parties under this Agreement. The
                  compensation for damages for such breach shall include any
                  damages suffered by Sumika or BioNumerik, whether direct or
                  indirect, including but not limited to damages suffered due to
                  loss of profits, business or good-will, provided that the
                  amount of such compensation shall not exceed the value of the
                  Compound sold and purchased between the Parties under this
                  Agreement.

12                FORCE MAJEURE

12.1 Neither Party shall be liable for delays or failure of performance of any
     obligation hereunder by reason of an Act of God, fire, flood, earthquake,
     war, public disaster, strike or labor difference, governmental enactment,
     rule or regulation, unforeseeable raw material shortages, transportation
     interruption or any other cause beyond such Party's control, provided that
     diligent continuing efforts are made to resume performance if such
     resumption is a commercially reasonable option. Written notice must be
     given to the other Party for any claim made under this clause.

<PAGE>

13                PUBLICITY AND PUBLICATIONS

13.1              Except as provided by this Agreement or as required by law,
                  neither Party shall originate any publicity, news release or
                  other public announcement, written or oral, whether to the
                  public press, or otherwise, relating to this Agreement, any
                  amendment hereto or performance hereunder, or the existence of
                  any arrangement between the Parties without the prior written
                  approval of the other Party, which approval shall not be
                  unreasonably withheld.

14                AUTHORIZATION AND NOTICES

14.1              All notices referred to herein shall be sent by prepaid
                  registered mail or by telefax and shall be deemed delivered if
                  sent to the addresses of the respective Parties hereinbelow
                  indicated, or such other address as is furnished by such
                  notice to other Party.

                  Notices and payments to Sumika shall be made to:

                  SUMIKA FINE CHEMICALS CO., LTD.
                  1-21, Utajima 3-chome
                  Nishiyodogawa-ku, Osaka 555-0021, Japan
                  Attn:    Mr. Katsuyki Imada, Assistant Manager,
                                               International Business Division
                           Dr. Naruhito Masai, Director International Business
                                               Division
                  Fax:     +81-6-6473-0503
                  Phone:   +81-6-6473-0574
                  e-mail : imada@sumika-fine-chem.co.jp
                           masai@sumika-fine-chem.co.jp

                  Notices and invoices to BioNumerik shall be made to:

                  BIONUMERIK PHARMACEUTICALS, INC.
                  Suite 1250,
                  8122 Datapoint Drive,
                  San Antonio, Tx 78229, USA
                  Attn:    Dr. Harry Kochat, Project Manager
                  Fax:     +1 210 614 9439
                  Phone:   +1 210 614 1701
                  e-mail:  harry.kochat@bnpi.com

                                       12

<PAGE>

                  with a copy to:

                  Frederick H. Hausheer, M.D.,
                  Chairman and CEO
                  BioNumerik Pharmaceuticals, Inc.,
                  Suite 1250,
                  8122 Datapoint Drive
                  San Antonio, TX 78229, USA
                  Fax:   +1 210 614 0643
                  Phone: +1 210 614 1701

15                ASSIGNMENT

15.1              This Agreement is deemed personal to BioNumerik and Sumika.
                  Neither Party shall, without prior written consent of the
                  other Party, assign this Agreement or any of its rights nor
                  delegate any of its duties or obligations herein. Without
                  prejudice to clause 10.4 e), both Parties agree not to
                  unreasonably withhold consent if such an assignment is
                  contemplated in connection with the sale or merger by a Party
                  of all or substantially all of its assets to a third Party,
                  providing the non-assigning Party receives and accepts such
                  written assurances of continued performance and commitments
                  from the assignee under this Agreement as it may reasonably
                  require prior to such an assignment becoming effective. Any
                  assignment or delegation in derogation of this provision shall
                  be deemed null and void.

16                GOVERNING LAW AND DISPUTES

16.1              THIS AGREEMENT IS MADE UNDER AND SHALL BE CONSTRUED IN
                  ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS, WITHOUT REGARD
                  TO THE CONFLICTS OF LAW PRINCIPLES THEREOF. ALL TRADE TERMS
                  PROVIDED IN THIS AGREEMENT SHALL BE INTERPRETED IN ACCORDANCE
                  WITH THE 1990 EDITION OF INCOTERMS ISSUED BY THE INTERNATIONAL
                  CHAMBER OF COMMERCE.

                  Each party to this Agreement hereby irrevocably consents and
                  submits to the jurisdiction of the courts of the State of
                  Texas and of the United States of America for all purposes in
                  connection with any proceeding which arises out of or relates
                  to this Agreement.

16.2              Any controversy or claim arising out of or relating to this
                  Agreement, or the breach thereof, shall be settled by
                  arbitration in accordance with the commercial arbitration
                  rules of the International Chamber of Commerce. The place of
                  any arbitration shall be (I) San Antonio, Texas, U.S.A. if
                  such arbitration is instituted by Sumika and (ii) Osaka, Japan
                  if instituted by BioNumerik. Judgment upon award rendered by
                  the arbitrator(s) may be entered in any court of competent
                  jurisdiction in the United States or Japan .

17                MISCELLANEOUS

17.1              WAIVERS: Failure of either Party at any time to require
                  strict performance by the other Party of any of the provisions
                  of the Agreement shall in no way affect the right thereafter
                  to enforce the same, nor shall the waiver of any term,
                  provision, covenant or condition hereof be taken or held to be
                  a waiver of any

                                       13
<PAGE>

                  subsequent breach thereof or as nullifying the effectiveness
                  of such term, provision, covenant or condition.

17.2              COUNTERPARTS: This Agreement may be executed in two or more
                  counterparts, which all together shall constitute one
                  instrument.

17.3              ENTIRE AGREEMENT: This Agreement and its annexes, as well as
                  the Confidentiality Agreement and the Materials Transfer
                  Agreement dated March 13, 2000 by and between BioNumerik and
                  Sumika, embody the entire understanding of the Parties and
                  shall supersede all previous communications, representations,
                  or understandings, either oral or written, between the Parties
                  relating to the subject matter hereof.

17.4              AMENDMENTS: No amendments or modifications of this Agreement
                  will be deemed legally binding unless made in writing and
                  signed by both Parties hereto.

17.5              SEVERABILITY: In case one or more of the provisions contained
                  in this Agreement shall, for any reason, be held invalid,
                  illegal, or unenforceable in any respect, such invalidity,
                  illegality or unenforceability shall not affect any other
                  provision of this Agreement, but this Agreement shall be
                  construed by amending or limiting such invalid, illegal, or
                  unenforceable provision so as to conform as closely as
                  possible to the intent of the Parties or, if such is not
                  possible, by deleting such provision from this Agreement.

17.6              ANNEXES: The Annexes form an integral part of this Agreement.
                  Should any internal discrepancies or variances occur between
                  this Agreement and its Annexes, the Agreement shall take
                  precedence.

17.7              HEADINGS: The headings in this Agreement may not be used in
                  the interpretation of any provisions hereof.

17.8              USE OF NAMES: Except as expressly required pursuant to law,
                  neither Party will without prior written consent of the other:

                  (a)      Use in advertising, publicity, promotional premiums
                           or otherwise, any trade name, trademark, trade
                           device, service mark, symbol, or any abbreviation,
                           contraction or simulation thereof owned by the other
                           Party, or

                  (b)      Represent, either directly or indirectly, that any
                           product or service of one Party is a product or
                           service of the other.

17.9              LANGUAGE: The Parties have requested that this Agreement and
                  all related documents be in English.

17.10             COPIES: This Agreement is established in two (2) copies with
                  identical language: One copy for BioNumerik and one copy for
                  Sumika.

                                       14

<PAGE>

In Witness Hereof,

                the Parties hereto through their authorized representatives have
                executed this Agreement as of the date first written above.

SUMIKA FINE CHEMICALS CO., LTD.

By:       \s\ Z. WAKAYASHI
         ----------------------------------------------

Title:   Managing Director, Marketing & Sales

Date:     4/10/01
         ----------------------------------------------

BIONUMERIK PHARMACEUTICALS, INC.

By:       \s\ FREDERICK H. HAUSHEER
         ----------------------------------------------

Title:   Chairman and Chief Executive Officer

Date:     4/12/01
         ----------------------------------------------

AGREED TO SECTION 7 AND ATTESTED BY:

GRELAN PHARMACEUTICAL CO., LTD.

By:       \s\ H. KANAZAWA
         ----------------------------------------------

Title:   C.O.O. and Vice President -- Director

Date:     4/12/01
         ----------------------------------------------

                                       15

<PAGE>

                                     ANNEX 1

                       QUALITY SPECIFICATIONS AND METHODS

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

<PAGE>

ANNEX 2         SUMIKA PRICE SCHEDULE

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

<PAGE>

ANNEX 3: SUMIKA WIRE TRANSFER INFORMATION

SUMITOMO MITSUI BANKING CORPORATION
     OSAKA HEAD OFFICE
     6-5 KITAHAMA, 4-CHOME, CHUO-KU,
     OSAKA 541-0041
     ACCOUNT NO. 2929482

<PAGE>
                                                                         ANNEX 4
                                                                       (3 Pages)

                 LIST OF DMF REQUIREMENTS DATA FOR BNP7787 AND

               RESPONSIBLE PARTY FOR DATA/INFORMATION ACQUISITION

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]